Scolaris Content Display Scolaris Content Display

Neuromuscular electrostimulation for adults with chronic obstructive pulmonary disease

Collapse all Expand all

Background

In people with chronic obstructive pulmonary disease (COPD), the use of neuromuscular electrostimulation (NMES) either alone, or together with conventional exercise training, might improve the condition of the peripheral muscles, increase exercise capacity and functional performance, reduce symptoms and improve health‐related quality of life (HRQoL).

Objectives

To determine the effects of NMES, applied in isolation or concurrently with conventional exercise training to one or more peripheral muscles, on peripheral muscle force and endurance, muscle size, exercise capacity, functional performance, symptoms, HRQoL and adverse events in people with COPD.

Search methods

We searched the Cochrane Airways Group Specialised Register, the Physiotherapy Evidence Database, clinical trial registries and conference abstracts on 14 March 2018.

Selection criteria

Randomised controlled trials that recruited adults with COPD if they had compared outcomes between a group that received NMES and a group that received usual care or compared outcomes between a group that received NMES plus conventional exercise training and a group that participated in conventional exercise training alone.

Data collection and analysis

Two review authors independently extracted data and assessed risk of bias using the Cochrane 'Risk of bias' tool. We expressed continuous data as either the standardised mean difference (SMD) or mean difference (MD) with the corresponding 95% confidence interval (CI). We assessed the quality of evidence using the GRADE approach.

Main results

Nineteen studies met the inclusion criteria of which 16 contributed data on 267 participants with COPD (mean age 56 to 76 years and 67% were men). Of these 16 studies, seven explored the effect of NMES versus usual care and nine explored the effect of NMES plus conventional exercise training versus conventional exercise training alone. Six studies utilised sham stimulation in the control group. When applied in isolation, NMES produced an increase in peripheral muscle force (SMD 0.34, 95% CI 0.02 to 0.65; low‐quality evidence) and quadriceps endurance (SMD 1.36, 95% CI 0.59 to 2.12; low‐quality evidence) but the effect on thigh muscle size was unclear (MD 0.25, 95% CI ‐0.11 to 0.61; low‐quality evidence). There were increases in six‐minute walk distance (6MWD) (MD 39.26 m, 95% CI 16.31 to 62.22; low‐quality evidence) and time to symptom limitation exercising at a submaximal intensity (MD 3.62 minutes, 95% CI 2.33 to 4.91). There was a reduction in the severity of leg fatigue on completion of an exercise test (MD ‐1.12 units, 95% CI ‐1.81 to ‐0.43). The increase in peak rate of oxygen uptake (VO2peak) was of borderline significance (MD 0.10 L/minute, 95% CI 0.00 to 0.19).

For NMES with conventional exercise training, there was an uncertain effect on peripheral muscle force (SMD 0.47, 95% CI ‐0.10 to 1.04; very low‐quality evidence) and there were insufficient studies to undertake a meta‐analysis on the effect on quadriceps endurance or thigh muscle size. However, there was an increase in 6MWD in favour of NMES combined with conventional exercise training (MD 25.87 m, 95% CI 1.06 to 50.69; very low‐quality evidence). In people admitted to either in an intensive care unit or a respiratory high dependency centre, NMES combined with conventional exercise reduced the time taken for participants to first sit out of bed by 4.98 days (95% CI ‐8.55 to ‐1.41; very low‐quality evidence), although the statistical heterogeneity for this analysis was high (I2 = 60%). For both types of studies (i.e. NMES versus usual care and NMES with conventional exercise training versus conventional exercise training alone), there was no risk difference for mortality or minor adverse events in participants who received NMES.

Authors' conclusions

NMES, when applied in isolation, increased quadriceps force and endurance, 6MWD and time to symptom limitation exercising at a submaximal intensity, and reduced the severity of leg fatigue on completion of exercise testing. It may increase VO2peak, but the true effect on this outcome measure could be trivial. However, the quality of evidence was low or very low due to risk of bias within the studies, imprecision of the estimates, small number of studies and inconsistency between the studies. Although there were no additional gains in quadriceps force with NMES plus conventional exercise training, there was evidence of an increase in 6MWD. Further, in people who were the most debilitated, the addition of NMES may have accelerated the achievement of a functional milestone, that is, the first time someone sits out of bed.

PICOs

Population
Intervention
Comparison
Outcome

The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.

See more on using PICO in the Cochrane Handbook.

Muscle stimulation for people with chronic obstructive pulmonary disease (COPD)

Review question

We reviewed the evidence for applying electrical stimulation to the thigh muscles of people with COPD (a long‐term lung condition characterised by cough, sputum production (fluids from the lungs, i.e. phlegm) and difficulty breathing). We looked at studies that used two groups; one receiving electrical stimulation by placing conductive pads over the muscle, the other receiving usual medical care. We also looked at studies that added electrical stimulation to an exercise programme and compared the results with a group that only undertook the exercise programme.

The studies measured muscle strength and endurance (how long the muscle could work), muscle size, exercise capacity, shortness of breath, leg fatigue and health‐related quality of life (HRQoL; a measure of a person's satisfaction with their life and health). We also looked to see if applying electrical stimulation to the muscles in the thigh caused any unwanted effects.

Background

People with COPD find exercise difficult and feel breathless. But exercise such as frequent brisk walking or stationary cycling reduces breathing difficulties and improves the ability to exercise. One way that exercise helps is by improving the condition (how well they work) of the thigh muscles.

However, for some people with COPD, exercising at a level that is high enough to improve the condition of the thigh muscles is difficult because they experience severe shortness of breath with exercise. In these people, it may be that using an electrical current to stimulate the thigh muscles will help to improve their condition. Because the electrical stimulation is applied to only a few muscles (in contrast to exercise, which involves several muscles), electrical stimulation can be completed without causing much shortness of breath. If electrical stimulation can improve the condition of the leg muscles, it might be a useful rehabilitation approach.

Search date

The evidence is current to March 2018.

Study characteristics

Nineteen studies met the inclusion criteria for the review, of which 16 had data on 267 participants that could be included in the analyses. The average age of people in each of the studies ranged from 56 to 76 years and 179 (67%) were men. Seven studies explored the effect of applying electrical stimulation alone and nine studies explored the effect of adding electrical stimulation to an exercise programme. Electrical stimulation was applied in a range of settings, such as at home, in an outpatient hospital department, on a hospital ward or in an intensive care unit. Most studies stimulated the thigh muscles once or twice a day for 30 to 60 minutes on four to seven days each week for four to eight weeks.

Key results

Studies that explored the effect of applying electrical stimulation alone showed an increase in strength and endurance of the thigh muscles. They showed an increase in some, but not all, measures of exercise capacity and a decrease in the severity of leg fatigue after exercise. Studies that explored the effect of adding electrical stimulation to an exercise programme showed a small increase in the distance walked in six minutes. In people who were most unwell (e.g. in an intensive care unit), adding electrical stimulation to an exercise programme helped people to spend fewer days confined to bed. Electrical stimulation did not increase the risk of side effects.

Quality of the evidence

The quality of evidence provided by this review was low. This is because most studies had design problems. The inclusion of future studies into this review is likely to change the results.

Authors' conclusions

available in

Implications for practice

When applied in isolation from other rehabilitation strategies, neuromuscular electrostimulation (NMES) applied to the quadriceps increases quadriceps force and quadriceps endurance. There are also improvements in six‐minute walk distance (6MWD), time to symptom limitation exercising at a submaximal intensity and the severity of leg fatigue on completion of an exercise test. It may increase peak rate of oxygen uptake (VO2peak), but the true effect on this outcome measure could be trivial. Therefore, in participants who are unable or unwilling to attend a pulmonary rehabilitation programme, consideration could be given to using NMES. Nevertheless, the quality of the evidence is low.

When applied with conventional exercise training, the effect of NMES on peripheral muscle force is uncertain. However, this result appears to have been influenced by the inclusion of a study that completed fewer than 10 sessions over four weeks. Exclusion of this study revealed a significant increase in peripheral muscle force. There was evidence for an increase in 6MWD, but this result appears to be influenced by the inclusion of a study that recruited people who were admitted to the intensive care unit (ICU) with an acute exacerbation of their disease. Evidence for additional benefit, over and above the effects seen with conventional exercise on symptoms or health‐related quality of life, was lacking. However, in people admitted to either an ICU or a respiratory high dependency unit, NMES combined with conventional exercise may accelerate the attainment of a functional milestone; that is, the time taken for participants to first sit out of bed. Therefore, it is likely that the addition of NMES strength protocol to a programme of exercise will be of most benefit to people who are experiencing or recovering from an exacerbation. However, again, the quality of the evidence is low.

Regardless of whether it was applied in isolation or together with conventional exercise training, NMES appears not to increase the risk of adverse events.

Implications for research

In people with COPD, given the evidence that pulmonary rehabilitation, which includes an obligatory exercise training component, changes outcomes such as 6MWD, symptoms and HRQoL (McCarthy 2015), in clinical practice, there would seem to be little basis to offer NMES as an alternative to exercise training. Therefore, the most relevant question regarding the use of NMES in people with COPD is: does adding NMES to a programme of conventional exercise training produce additional benefits over and above those seen following conventional exercise training alone? The NMES protocols described in the studies included in this review were diverse and often did not use parameters that specifically targeted strength or endurance adaptations; a factor that may have dampened its effect. Future studies should give consideration to the type of adaptation (i.e. strength or endurance) that is most desirable in response to a programme of NMES (Dolmage 2016). In people who are most debilitated and lack the strength to complete everyday activities (such as moving from sit to stand), protocols that maximise strength adaptations are likely to be necessary before participation in an exercise training programme is appropriate. In contrast, in people who have adequate strength for everyday activities, but experience difficulty engaging in effective aerobic exercise due to intolerable dyspnoea (i.e. people referred to a pulmonary rehabilitation programme), protocols that maximise endurance adaptations are likely to be the most appropriate. The impact of these protocols on muscle endurance, rather than just muscle strength, needs to be explored. Regarding other outcome measures, studies should consider evaluating the effect of NMES on measures such as VO2peak, as well as measures that are known to be most responsive such as time to symptom limitation exercising at a high constant power and the progression of symptoms during exercise (e.g. iso‐time responses). Finally, the characteristics of 'responders' to NMES requires further exploration.

Summary of findings

Open in table viewer
Summary of findings for the main comparison. NMES compared to usual care (with or without sham NMES) for COPD

NMES compared to usual care (with or without sham NMES) for COPD

Patient or population: COPD

Setting: generally outpatient or home

Intervention: NMES

Comparison: usual care (with or without sham NMES)

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

№ of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Risk with usual care (with or without sham NMES)

Risk with NMES

Peripheral muscle force

assessed with: any method

SMD 0.34 SD higher
(0.02 higher to 0.65 higher)

159
(6 RCTs)

⊕⊕⊝⊝
Lowa

In real terms, using data available in 1 study that reported changes in quadriceps force in kg (Maddocks 2016), an SMD of 0.34 was equivalent to a difference in force of 3.1 kg (from a baseline mean force of 23.1 kg).

Peripheral muscle endurance/fatigability

assessed with: any method

SMD 1.36 SD higher
(0.59 higher to 2.12 higher)

35
(2 RCTs)

⊕⊕⊝⊝
Lowb

Thigh muscle size assessed with: any method

SMD 0.25 SD higher
(0.11 lower to 0.61 higher)

124
(4 RCTs)

⊕⊕⊝⊝
Lowc

Exercise capacity

assessed with: 6MWD (m)

The mean change in 6MWD in the control group ranged from ‐5.70 m to 0.80 m

MD 39.26 m more
(16.31 more to 62.22 more)

72
(2 RCTs)

⊕⊕⊝⊝
Lowd

Functional performance

assessed with: time (days) until first sit out of bed

None of the studies reported on functional performance.

Symptoms of dyspnoea reported on completion of an exercise test

assessed with: Borg score

The mean change in dyspnoea reported on completion of an exercise test ranged from ‐0.50 to 0.40

MD 1.03 less dyspnoea
(2.13 less to 0.06 more)

55
(3 RCTs)

⊕⊝⊝⊝
Very lowe

Health‐related quality of life

assessed with: SGRQ

The mean change in HRQoL ranged from ‐2.00 to 0.07

MD 4.12 better
(12.60 better to 4.35 worse)

72
(2 RCTs)

⊕⊝⊝⊝
Very lowf

Minor adverse events

assessed: related to intervention only (e.g. redness)

5970 per 100,000

0 per 100,000
(‐418 to 418)

RD 0.00
(‐0.07 to 0.07)

139
(5 RCTs)

⊕⊕⊝⊝
Lowg

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

6MWD: 6‐minute walk distance; CI: confidence interval; COPD: chronic obstructive pulmonary disease; MD: mean difference; NMES: neuromuscular electrical stimulation; RCT: randomised controlled trials; RD: risk difference; SD: standard deviation; SGRQ: Saint George's Respiratory Questionnaire; SMD: standardised mean difference.

GRADE Working Group grades of evidence
High quality: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low quality: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low quality: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

aDowngraded one level due to risk of bias (three studies did not use sham stimulation) and one level due to imprecision (wide confidence intervals).

bDowngraded one level due to risk of bias (one study did not use sham stimulation) and one level due to small number of studies available for analyses.

cDowngraded one level due to risk of bias (one study did not use sham stimulation) and one level due imprecision (wide confidence intervals).

dDowngraded one level due to small number of studies available for analyses and one level due imprecision (wide confidence intervals).

eDowngraded one level due to risk of bias (one study did not use sham stimulation), one level for imprecision (wide confidence intervals) and one level for inconsistency.

fDowngraded one level due to small number of studies available for analyses, one level for imprecision (wide confidence intervals) and one level due to inconsistent findings.

gDowngraded one level due to risk of bias (two studies did not use sham stimulation) and one level for inconsistent findings.

Open in table viewer
Summary of findings 2. NMES and exercise compared to exercise (with or without sham NMES) for COPD

NMES and exercise compared to exercise (with or without sham NMES) for COPD

Patient or population: COPD

Setting: intensive care unit, inpatient rehabilitation, outpatient or home

Intervention: NMES + exercise

Comparison: exercise (with or without sham NMES)

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

№ of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Risk with exercise (with or without sham NMES)

Risk with NMES and exercise

Peripheral muscle force

assessed with: any method

SMD 0.47 SD higher
(‐0.10 higher to 1.04 higher)

84
(4 RCTs)

⊕⊝⊝⊝
Very lowa

Peripheral muscle endurance/fatigability

assessed with: any method

None of the studies reported peripheral muscle endurance/fatigability.

Thigh muscle size assessed with: any method

None of the studies reported thigh muscle size.

Exercise capacity

assessed with: 6MWD (m)

The mean change in 6MWD ranged from 10.30 m to 94.00 m

MD 25.87 m more
(1.06 more to 50.69 more)

138
(6 RCTs)

⊕⊝⊝⊝
Very lowb

Functional performance

assessed with: time (days) until first sit out of bed

The mean time until first sit out of bed ranged from 12.60 to 14.33 days

MD 4.98 fewer days
(8.55 to 1.41 fewer)

44
(2 RCTs)

⊕⊝⊝⊝
Very lowc

Symptoms of dyspnoea reported on completion of an exercise test

assessed with: Borg score

The mean change in dyspnoea reported on completion of an exercise test ranged from ‐0.62 units to 1.00 units

MD 0.44 less dyspnoea
(2.27 less to 1.38 more)

44
(2 RCTs)

⊕⊝⊝⊝
Very lowd

Health‐related quality of life

assessed with: any validated questionnaire

SMD 0.56 SD better
(1.27 better to 0.15 worse)

122
(5 RCTs)

⊕⊝⊝⊝
Very lowe

Minor adverse events
assessed: related to intervention only (e.g. redness)

0 per 1000

0 per 1000
(0 to 0)

Not estimable

144
(6 RCTs)

⊕⊕⊝⊝

Lowf

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

6MWD: 6‐minute walk distance; CI: confidence interval;COPD: chronic obstructive pulmonary disease; MD: mean difference; NMES: neuromuscular electrical stimulation; RCT: randomised controlled trials; SD: standard deviation; SMD: standardised mean difference.

GRADE Working Group grades of evidence
High quality: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low quality: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low quality: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

aDowngraded one level due to risk of bias (three studies did not use sham stimulation), one level due to imprecision (wide confidence intervals) and one level due to inconsistent findings.

bDowngraded one level due to risk of bias (five studies did not use sham stimulation), one level due to imprecision (wide confidence intervals) and one level due to inconsistent findings.

cDowngraded one level due to risk of bias (neither study used sham stimulation), one level due imprecision (wide confidence intervals) and one level due to small number of studies available for analyses.

dDowngraded one level due to risk of bias (one study did not use sham stimulation), one level due imprecision (wide confidence intervals) and small number of studies available for analyses, and one level for inconsistent findings.

eDowngraded one level due to risk of bias (four studies did not use sham stimulation), one level for imprecision (wide confidence intervals) and one level for inconsistency.

fDowngraded one level due to risk of bias (four studies did not use sham stimulation) and one level for imprecision (wide confidence intervals).

Background

available in

Description of the condition

Chronic obstructive pulmonary disease (COPD) is a condition characterised by persistent expiratory airflow limitation (Vogelmeier 2017). It is also associated with several systemic manifestations, including profound deconditioning of the peripheral muscles (Maltais 2014). The prevalence of COPD that is of at least moderate severity among adults over 40 years of age is approximately 10% (Buist 2007). The cardinal complaint of people with this condition is dyspnoea (Vogelmeier 2017). One updated Cochrane Review suggested that, in people with COPD, pulmonary rehabilitation that includes conventional exercise training will increase exercise tolerance, reduce symptoms of dyspnoea and fatigue, and improve health‐related quality of life (HRQoL) (McCarthy 2015). This appears to relate to a reduction in the signs suggestive of muscle deconditioning, such as early lactic acid accumulation (Casaburi 1991). Nevertheless, amongst people with the most marked ventilatory limitation to exercise, intolerable dyspnoea may preclude the application of a training stimulus to the peripheral muscles that is of sufficient intensity to confer a training adaptation. For this reason, there is interest in the use of strategies to optimise the training load borne by the muscles of locomotion, particularly the quadriceps (Hill 2014). One such strategy is the use of neuromuscular electrostimulation (NMES). This involves eliciting a muscle contraction by applying an intermittent electrical current to a superficial peripheral muscle (Maffiuletti 2010).

Description of the intervention

NMES involves placing conductive pads over the muscle and using an intermittent electrical current to trigger action potentials, activate the intramuscular nerve branches and muscle fibres to generate a strong muscle contraction (Maffiuletti 2010). The conductive pads are attached to a preprogrammed stimulation unit. Stimulation parameters can be manipulated to favour a pattern of contractions that promote strength or endurance adaptations in the muscle. For example, protocols aimed at a strength adaptation may comprise few contractions, using high‐frequency stimulation to ensure highest possible force, performed at the highest tolerable current to maximise the number of muscle fibres recruited (Maffiuletti 2010). A relatively long contraction period followed by an even longer rest period may be advantageous (Filipovic 2011). These protocols, which commonly feature in studies undertaken in people with COPD, aim to create the greatest force during each and every contraction because the mechanical stress is likely to stimulate synthesis of the contractile proteins (Murton 2010). Protocols aimed at an endurance adaptation may comprise multiple relatively frequent and brief contractions over prolonged periods. Relatively short contractions interspersed with short rest periods may be advantageous (Nuhr 2004). These protocols aim to mimic repeated contractions to elevate metabolism and accumulation of products that stimulate mitochondrial biogenesis (and inhibit protein synthesis, i.e. strength adaptations) (Takahashi 1993). The highest intensity tolerated may be used for both strength and endurance protocols, because maximising the intensity of stimulation increases the number of fibres stimulated. This is important because, unlike with voluntary contractions, orderly recruitment of the muscle fibres does not occur with transcutaneous stimulation (Gregory 2005; Henneman 1985). The muscle group most commonly targeted by NMES is the quadriceps.

How the intervention might work

NMES may be used to target increases in peripheral muscle strength or endurance. Targeting gains in strength may be most appropriate for people who are very debilitated (e.g. intensive care unit ((ICU) survivors) and lack the strength required to undertake everyday activities (e.g. rise from sitting to standing). In contrast, targeting gains in endurance may be most appropriate for people who are unable to achieve adequate intensity during aerobic exercise due to the onset of intolerable dyspnoea (e.g. in people with severe disease or during exacerbations of the disease) (Parker 2005). Specifically, aerobic exercise training, such as brisk walking or cycling, involves many muscles, including postural muscles, which must be supported by the ventilatory system. In people with COPD, the ventilatory system is compromised and therefore the duration that an effective training stimulus can be sustained during aerobic exercise is often constrained by intolerable dyspnoea (Maltais 1997). In contrast, NMES isolates contracting muscle groups, thereby lessening the overall ventilatory load (Sillen 2011). For this reason, in people with COPD who experience dyspnoea so severe that it precludes them from participating in aerobic exercise training at sufficient intensity to condition the peripheral muscles, NMES might be an appropriate option. As impairments in exercise capacity have been related to decrements in quadriceps function (Maltais 2000; Saey 2003), it is likely that conditioning these muscles via NMES will increase exercise capacity.

Why it is important to do this review

The aim of this review was to determine the effects of NMES, applied in isolation or concurrently with conventional exercise training, on peripheral muscle force and endurance, muscle size, exercise capacity, functional performance, symptoms, HRQoL and adverse events in adults with COPD. The results of this review will provide clinicians who work in the area of pulmonary rehabilitation, as well as clinicians who treat people hospitalised with an acute exacerbation of COPD, with information to guide their decisions regarding whether or not to use this approach.

Objectives

available in

To determine the effects of NMES, applied in isolation or concurrently with conventional exercise training to one or more peripheral muscles, on peripheral muscle force and endurance, muscle size, exercise capacity, functional performance, symptoms, HRQoL and adverse events in people with COPD.

Methods

available in

Criteria for considering studies for this review

Types of studies

Randomised controlled trials (RCTs) only were eligible for inclusion, as they are the gold standard study design for determining the effectiveness of an intervention. We excluded randomised cross‐over trials.

Types of participants

Adults with a diagnosis of COPD regardless of their clinical stability; that is, studies that recruited people with stable COPD or people with an exacerbation of COPD. We included studies that recruited a sample of participants with a range of chronic respiratory diseases only if most participants (greater than 50%) had a diagnosis of COPD.

Types of interventions

  • NMES (of any peripheral muscle) compared with usual care (any aspect of usual medical care, with or without sham training NMES, but not conventional exercise training). This allowed us to determine the effects of NMES in isolation from other exercise rehabilitation strategies.

  • NMES (of any peripheral muscle) plus conventional exercise training (which included active limb movement if the participants were hospitalised) compared with conventional exercise training alone, with or without sham training NMES. This allowed us to determine the effects of using NMES as an adjunct to conventional exercise training.

Types of outcome measures

Primary outcomes

  • Peripheral muscle force (using any method): defined as the peak force (or torque) elicited during a maximum voluntary contraction or a twitch force elicited in response to stimulation of a peripheral nerve.

  • Peripheral muscle endurance/fatigability (using any method): defined as performance during any test that aimed to elicit a decline in muscle force over time using repeated muscle contractions.

  • Thigh muscle size (using any method).

For these muscle‐specific outcomes, we extracted measurements made before and after the intervention period.

  • Serious adverse events (e.g. mortality) recorded during the intervention period only.

Because NMES aims to condition the peripheral muscles, muscle‐specific outcomes were selected as the primary outcomes for this study. Serious adverse events were also selected as a primary outcome as information on this outcome will assist clinicians in determining whether or not NMES poses a risk to people with COPD.

Secondary outcomes

  • Exercise capacity (e.g. six‐minute walk distance (6MWD), incremental shuttle walk distance, performance during an endurance shuttle walk test (ESWT), peak rate of oxygen uptake (VO2peak), peak power, lactate threshold, time to symptom limitation during a constant submaximal power test, changes in cardiorespiratory measures taken at iso‐time).

  • Functional performance (e.g. Timed Up and Go test or capacity to get out of bed independently).

  • Symptoms of dyspnoea and fatigue (using any validated questionnaire or scale).

  • Health‐related quality of life (using any validated disease‐specific HRQoL questionnaire).

For outcomes of exercise capacity, functional performance, symptoms and HRQoL, we extracted measurements made before and after the intervention period.

  • Minor adverse events recorded during the intervention period only (e.g. discomfort, musculoskeletal pain, muscle soreness, skin irritation).

Exercise capacity, measures of functional performance, symptoms and HRQoL are outcomes that are perceived to be important by patients. That is, any improvement in muscle function following NMES is unlikely to be perceived as important by the patient, unless the effect translates into an improvement in exercise capacity, measures of functional performance, symptoms of dyspnoea and fatigue or HRQoL.

Reporting of one or more of the outcomes listed here was not an inclusion criterion for the review.

Search methods for identification of studies

Electronic searches

We searched the following databases:

  • the Cochrane Airways Trials Register;

  • the Physiotherapy Evidence Database (PEDro).

The Cochrane Airways Trials Register is maintained by the Information Specialist for the Group. It contains studies identified from several sources:

  • monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL), through the Cochrane Register of Studies Online (crso.cochrane.org);

  • weekly searches of MEDLINE OvidSP from 1946 to date of search;

  • weekly searches of Embase OvidSP from 1974 to date of search;

  • monthly searches of PsycINFO OvidSP from 1967 to date of search;

  • monthly searches of CINAHL EBSCO (Cumulative Index to Nursing and Allied Health Literature) from 1937 to date of search;

  • monthly searches of AMED EBSCO (Allied and Complementary Medicine);

  • handsearches of the proceedings of major respiratory conferences.

Studies contained in the Cochrane Airways Trials Register are identified through search strategies based on the scope of Cochrane Airways. Details of these strategies, and a list of handsearched conference proceedings are in Appendix 1. Records in the Cochrane Airways Trials Register were searched using the strategy outlined in Appendix 2. This strategy was adapted to search PEDro. The most recent search was conducted on 14 March 2018.

We searched ClinicalTrials.gov (www.ClinicalTrials.gov) and the World Health Organization trials portal (www.who.int/ictrp/en/). We searched all databases from their inception to the date of search, and imposed no restrictions on language of publication or publication status.

Searching other resources

We checked reference lists of all primary studies and review articles for additional references and relevant manufacturers' websites for trial information. We contacted investigators who were prominent in this field to ask about unpublished or ongoing studies.

We handsearched abstracts presented at the World Confederation for Physical Therapy ‐ congress meetings from 2003, 2007, 2011, 2015 and 2017.

We searched for errata or retractions from included studies published in full text on PubMed (www.ncbi.nlm.nih.gov/pubmed).

Data collection and analysis

Selection of studies

Two groups of review authors (KH and SM or KH and VC) independently screened the titles and abstracts of all studies identified as a result of the search and coded them as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve.' We retrieved the full‐text study reports/publications, and two review authors (KH and SM or KH and VC) independently screened the full text and identified studies for inclusion. We recorded the reasons for exclusion of ineligible studies. We resolved disagreements through discussion. We identified and excluded duplicates and collated multiple reports of the same study, so that each study, rather than each report, was the unit of interest in the review. The selection process was recorded in sufficient detail to complete a PRISMA flow diagram and a Characteristics of excluded studies table.

Studies reported as full text, those published as abstracts only and unpublished data were eligible for inclusion.

Data extraction and management

We used an electronic data collection form related to study characteristics and outcomes after it was piloted on two studies included in the review. We extracted the following study characteristics.

  • Methods: study design, total duration of study, details of any 'run‐in' period, number of study centres and locations, study setting, withdrawals, date of study and details to allow an assessment of the risk of bias.

  • Participants: number, mean age, age range, gender, severity of condition, diagnostic criteria, presence (or not) of a recent (four weeks or less) acute exacerbation of their disease, baseline lung function, smoking history, inclusion criteria and exclusion criteria.

  • Interventions: NMES training and, where relevant, sham training parameters (including stimulation current, force of stimulated contraction, current ramp, pulse width, stimulation frequency, on time, duty cycle, frequency of exposure, duration of therapy and muscles stimulated).

  • Outcomes: data related to both primary and secondary outcomes assessed before (i.e. baseline) and after the intervention period. We extracted baseline data, postintervention data (i.e. measures of central tendency, measures of dispersion and sample size) and data pertaining to the change from baseline (or, where possible, calculated using baseline and postintervention data).

  • Notes: funding for trial and notable conflicts of interest of trial authors.

For each study, two review authors (SM, PR, TJF, MR or VC and KH) independently extracted data from included studies. We resolved disagreements by consensus. If outcome data were not reported in a usable way, we contacted the study authors to seek clarification. When we were unable to contact the authors, it was noted in the Characteristics of included studies table that data were not reported in a usable way. Once data extraction was complete, one review author (KH) transferred data into the Review Manager 5 (RevMan 2014). We double‐checked data to ensure that they had been entered correctly by comparing the data presented in the systematic review with that provided in the study reports. A second review author (VC) spot‐checked study characteristics for accuracy against the trial report.

We analysed measures of peripheral muscle force and endurance, muscle size, exercise capacity, functional performance, symptoms of dyspnoea and fatigue and HRQoL as continuous data. We reported adverse events as dichotomous outcomes (yes/no).

We presented data reported using scales (e.g. quadriceps endurance and HRQoL) with a consistent direction of effect.

Assessment of risk of bias in included studies

Two groups of review authors (KH and SM or KH and VC) independently assessed the risk of bias for each study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We resolved disagreements by discussion. We assessed the risk of bias according to the following domains.

  • Random sequence generation.

  • Allocation concealment.

  • Blinding of participants and personnel.

  • Blinding of outcome assessment.

  • Incomplete outcome data.

  • Selective outcome reporting.

  • Other bias.

In the 'Risk of bias' table, we graded each potential source of bias as high, low or unclear and provided a quote from the study report, together with a justification for our judgement. We summarised the risk of bias judgements across different studies for each of the domains listed. We described the implications of a lack of blinding separately for different key outcomes. When information on risk of bias related to unpublished data or correspondence with an investigator, we noted this in the 'Risk of bias' table.

When considering the quality of the evidence for treatment effects, we took into account the risk of bias for the studies that contributed to each outcome.

Assessment of bias in conducting the systematic review

We conducted the review according to the published protocol (Hill 2013), and reported deviations from it in the Differences between protocol and review section.

Measures of treatment effect

For dichotomous data, we calculated the risk difference (RD) and their 95% confidence intervals (CI). For continuous data that were reported using different units of measurement, we calculated the standardised mean differences (SMD) and their corresponding 95% CI using the change scores together with the standard deviation (SD) of the baseline measures in both groups. For continuous data that were reported using the same units of measurement, we calculated the mean differences (MD) and their corresponding 95% CI using the changes scores and the SD of the change scores in both groups. For studies that did not report the SD of the change scores, we used the SD of the baseline measures in both groups.

We undertook meta‐analyses only when meaningful (i.e. when treatments, participants and the underlying clinical question were similar enough for pooling to make sense).

We extracted skewed data as medians, interquartile ranges or range and converted them to mean and SDs using online software (Wen 2011), and used them in meta‐analyses that estimated MD. However, we did not included studies that reported outcome data as median, maximum and minimum values, or interquartile range in meta‐analyses that estimated SMD (Abdellaoui 2011; Akar 2017; Tasdemir 2015).

Unit of analysis issues

For studies that randomly assigned participants to groups (i.e. either NMES or control), the unit of analysis was the participant. For studies that randomly assigned one limb of a person to receive NMES and the other limb to receive control, the unit of analysis was the limb. We accept that inclusion of these studies may dampen our effect size for the results of NMES on muscle function because NMES may produce systemic effects such as improvement in microcirculation and increased heart rate response, which result in contralateral leg facilitation (Gerovasili 2009; Hortobágyi 1999). To address this issue, we undertook a sensitivity analysis, in which we excluded studies that used this design to see whether this changed our estimate of the effect.

Dealing with missing data

We contacted investigators to verify key study characteristics and to obtain missing outcome data (e.g. when a study was identified as an abstract only).

Assessment of heterogeneity

We used the I2 statistic to measure statistical heterogeneity among the trials in each analysis. We explored possible causes of substantial heterogeneity (I2 of 50% or greater) through sensitivity analyses.

Assessment of reporting biases

If we were able to pool more than 10 trials for any one meta‐analysis, we planned to create a funnel plot to examine possible publication and small‐study biases. Where available, we reviewed protocols published on clinical trial registries to explore reporting bias.

Data synthesis

We expected that some disparity would be present in the way NMES was applied between the studies, and that would introduce heterogeneity to the effects of the intervention. Therefore, we used a random‐effects model for the meta‐analyses.

'Summary of findings' table

We created a 'Summary of findings' table using the following outcomes: peripheral muscle force, peripheral muscle endurance, thigh muscle size, 6MWD, functional performance, dyspnoea, HRQoL and minor adverse events. We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of a body of evidence as it related to the studies that contributed data to the meta‐analyses for the prespecified outcomes (Guyatt 2008). We also presented results of subgroup analyses. We applied methods and recommendations described in Section 8.5 and Chapter 12 of the Cochrane Handbook for Systematic Reviews of Interventions using GRADEpro software (Higgins 2011). We justified all decisions to downgrade or upgrade the quality of studies in the table to aid the reader's understanding of the review.

Subgroup analysis and investigation of heterogeneity

For each analysis (i.e. NMES versus usual care, and NMES plus conventional exercise training versus conventional exercise training alone), we planned the following subgroup analyses.

  • Studies that recruited participants who were clinically stable versus studies that recruited participants during an acute exacerbation of COPD. This allowed us to explore whether the effectiveness of NMES differed between people who were clinically stable versus those who were experiencing an acute exacerbation of their disease.

  • Studies that used stimulation frequencies less than 15 Hz versus studies that used stimulation frequencies of 15 Hz or greater (Sillen 2011). This separated studies that used frequencies more likely to result in pulse fusion, a tetanic muscle contraction and favour strength adaptations (i.e. 15 Hz or greater) from those that did not (i.e. less than 15 Hz) and may assist in determining the most effective stimulation parameters.

  • Studies that recruited participants with, on average, severe disease (i.e. forced expiratory volume in one second (FEV1) less than 50%) versus studies that recruited participants with, on average, less severe disease (FEV1 of 50% or greater). This allowed us to explore whether the effectiveness of NMES differed between people with mild and moderate disease versus people with severe or very severe disease.

  • Studies that used robust, reliable methods for quantifying peripheral muscle force (i.e. via a mechanical dynamometer, fixed strain gauge or a twitch force elicited in response to stimulation of a peripheral nerve and measured with a strain gauge) versus studies that used less robust measures (i.e. via a hand‐held or non‐fixed dynamometer, the one‐repetition maximum or by applying the Medical Research Council grading system for manual muscle testing) (Clarkson 2000). This was important, as some outcome measures (e.g. Medical Research Council grading system for manual muscle testing) were likely to be less responsive to change than others (e.g. a mechanical dynamometer) and may have been at higher risk of detection bias.

  • Studies in which a minimum of 10 training sessions were completed within a four‐week period versus studies in which fewer than 10 training sessions were completed over this period. This allowed us to explore whether 'dose' influenced effectiveness.

We used the following outcomes in the subgroup analyses.

  • Muscle‐specific outcome measures such as peripheral muscle force, muscle endurance and muscle size.

  • Exercise capacity.

Sensitivity analysis

We conducted sensitivity analyses by excluding studies that described the use of different methodologies (e.g. studies that randomly assigned one limb of a person to receive NMES and the other limb to receive control).

Results

Description of studies

Nineteen (28 records) studies met the criteria to be included in this review (Figure 1). Of these, 16 contributed data for the meta‐analyses (Abdellaoui 2011; Akar 2017; Akinlabi 2013; Bourjeily‐Habr 2002; Dang 2011; Giavedoni 2012; Kucio 2016; Latimer 2013; Maddocks 2016; Neder 2002; Tardif 2015; Tasdemir 2015; Vieira 2014; Vivodtzev 2006; Vivodtzev 2012; Zanotti 2003), and one had data that were included in the narrative discussion (Dolmage 2016).


Study flow diagram.

Study flow diagram.

Results of the search

The search strategy yielded 159 potential studies, of which 38 were duplicates that were removed as part of the electronic search process. Of the 121 remaining potential studies, 32 records were excluded based on title or abstract and 40 studies (56 records) were excluded after reading the full paper (Figure 1). We identified four ongoing studies (ChiCTR‐IPR‐16009845; JPRN‐UMIN000024443; NCT01799330; NCT02321163), and one study reported in a conference abstract that we need further information to assess for inclusion (Chen 2017). Of the 19 studies (28 records) that met the criteria for inclusion, three provided no data that could be included in any meta‐analyses (Dolmage 2016; Gigliotti 2004; Zanotti 2010). Of the 16 studies included in the meta‐analyses, seven explored the effect of NMES versus usual care (Bourjeily‐Habr 2002; Giavedoni 2012; Latimer 2013; Maddocks 2016; Neder 2002; Vieira 2014; Vivodtzev 2012; Table 1), and nine explored the effect of NMES plus conventional exercise training versus conventional exercise training alone (Abdellaoui 2011; Akar 2017; Akinlabi 2013; Dang 2011; Kucio 2016; Tardif 2015; Tasdemir 2015; Vivodtzev 2006; Zanotti 2003; Table 2). A total of 13 studies recruited participants who were clinically stable (Akinlabi 2013; Bourjeily‐Habr 2002; Dang 2011; Kucio 2016; Latimer 2013; Maddocks 2016; Neder 2002; Tardif 2015; Tasdemir 2015; Vieira 2014; Vivodtzev 2006; Vivodtzev 2012; Zanotti 2003), and three recruited participants during hospitalisation for an exacerbation (Abdellaoui 2011; Akar 2017; Giavedoni 2012). One study recruited participants who had recently spent a period in the ICU or had been hospitalised with acute exacerbation (or both), and were transferred to an inpatient rehabilitation facility (Vivodtzev 2006). However, at the time of recruitment, participants in this study were clinically stable (Vivodtzev 2006). One study recruited participants who were referred to a respiratory high dependency unit from surrounding ICUs and who were ventilated via a tracheostomy for chronic respiratory failure (Zanotti 2003). However, at the time of recruitment, participants in this study were also clinically stable (Zanotti 2003). One study randomised participants to three intervention arms, but we only extracted data on the groups that received NMES plus conventional exercise training or conventional exercise training alone (Akar 2017). Two studies randomly assigned one leg to receive NMES and used the other leg to receive control (Giavedoni 2012; Latimer 2013). The latest search was run on 14 March 2018.

Open in table viewer
Table 1. Characteristics of studies that contributed data to meta‐analyses (NMES versus usual care)

Study

Setting

Lower limb stimulation

Clinical stability

Dose

Frequency (Hz)

Intervention received by control group

Bourjeily‐Habr 2002

Outpatient

Bilateral quadriceps, hamstrings and calf

Stable

20 min per day, 3 days per week for 6 weeks at an intensity that elicited a muscle contraction, and increasing by 5 mA per week

50

Sham stimulation

Giavedoni 2012

Hospital ward then at home

Unilateral quadriceps

Acute exacerbation

30 min per day, once per day for 14 days at maximum tolerated current

50

Nil

Latimer 2013

Combination of supervised and unsupervised home training

Unilateral quadriceps

Stable

30 min per session,
5 times per week, for 6 weeks at maximum tolerated current

50

Nil

Maddocks 2016

Home

Bilateral quadriceps

Stable

30 min per day, 7 days per
week for 6 weeks with current set to elicit a contraction equivalent to 15‐25% of a maximum voluntary contraction

50

Sham stimulation

Neder 2002

First week as outpatient then home

Bilateral quadriceps

Stable

15 min (to each leg) in the first
week which increased to 30 min thereafter, for 5 days per week for 6 weeks at maximum tolerated current

50

Nil

Vieira 2014

Presumably home

Bilateral quadriceps

Stable

60 min per session, 2 times per day, 5 days per week, for 8 weeks at maximum tolerated current

50

Both groups received respiratory physical therapy (i.e. airway clearance) as indicated as well as stretching exercises for the upper limbs, lower limbs and back (control group also received sham stimulation).

Vivodtzev 2012

Home

Bilateral quadriceps and calf

Stable

60 minutes per session, 5 days per week for 6 weeks at maximum tolerated current

50

Sham stimulation

min: minute; NMES: neuromuscular electrostimulation.

Open in table viewer
Table 2. Characteristics of studies that contributed data to meta‐analyses (NMES + exercise versus exercise alone)

Study

Setting

Lower limb stimulation

Clinical stability

Dose

Frequency (Hz)

Exercise intervention received by control group

Abdellaoui 2011

Intensive care unit

Bilateral quadriceps and hamstrings

Acute exacerbation

1 hour per day, 5 days per week for 6 weeks at maximum tolerated current

35

Both groups received education (once per week) and daily active‐passive mobilisation (control group also received sham stimulation).

Akar 2017

Intensive care unit

Bilateral quadriceps

Respiratory failure

5 days per week (total of 20 sessions) at maximum tolerated current

50

Both groups received active exercise, which comprised active joint range of motion exercise for upper and lower limbs. Participants who could not manage active exercise received active‐assisted or passive range of motion exercise.

Akinlabi 2013

Home

Bilateral quadriceps and hamstrings

Stable

2 days per week for 8 weeks (total of 16 sessions)

10‐50

Low‐intensity symptom‐limited exercise

Dang 2011

Outpatient

Bilateral quadriceps

Stable

36 min, 3 sessions per week for 12 weeks (total of 36 sessions) at maximum tolerated current

8‐45

Usual respiratory rehabilitation (no other details given)

Kucio 2016

Inpatient rehabilitation

Bilateral quadriceps and calf

Stable

36 min, presumably 6 supervised
sessions per week for 3 weeks, intensity not specified

35

Both groups received breathing exercises, treadmill walking and resistance exercise.

Tardif 2015

Home

Bilateral quadriceps

Stable

Presumably 30 min per day, 5 days per week, presumably for 8 weeks at maximum tolerated current

35

Both groups received pulmonary rehabilitation.

Tasdemir 2015

Outpatient

Bilateral quadriceps

Stable

20 min, 2 days per week for 10 weeks at maximum tolerated current

50

Both groups received pulmonary rehabilitation (control group also received sham stimulation).

Vivodtzev 2006

Inpatient rehabilitation

Bilateral quadriceps

Stable, but shortly following acute illness

> 30 min per session, 4 times per week, for 4 weeks at maximum tolerated current

5‐35

Both groups received active limb exercises. The strongest participants also performed walking on a treadmill together with 5‐10 min of resistance arm exercises. They also completed health education sessions 1 day per week.

Zanotti 2003

Respiratory high dependency unit for inpatient rehabilitation

Bilateral quadriceps and gluteals

Stable, but shortly following acute illness

Up to 30 min per session, 2 times per day, 5 days per week for 4 weeks presumably at maximum tolerated current

8‐35

Both groups received rehabilitation that comprised active limb exercises.

min: minute; NMES: neuromuscular electrostimulation.

Included studies

With the exception of risk of bias, the results refer only to studies that provided data that could be incorporated into the review.

Participants

The 16 studies contributed data on 267 participants with COPD, of whom 150 (56%) received NMES. The mean age of the participants ranged from 56 to 76 years and 179 (67%) were men. The mean FEV1 of the participants ranged from 15% to 50% of the predicted value in healthy adults. Common inclusion criteria related to a diagnosis of severe or very severe COPD and severe functional limitation due to dyspnoea. Common exclusion criteria were the presence of an implanted cardiac pacemaker or comorbidities that may have interfered with participation in the study. For further description of the participants included in the studies in these meta‐analyses, refer to the Characteristics of included studies table.

Intervention

The intervention was undertaken:

One study did not state the location for the intervention (Vieira 2014), but it was likely that this study provided the intervention in the home.

The lower limb muscles stimulated were:

Both studies that randomly assigned one leg to receive NMES and used the other leg to receive control stimulated only unilateral quadriceps (Giavedoni 2012; Latimer 2013).

Regarding intensity, when described (either in the paper or through communication with the authors), most studies reported that stimulation was set to the maximum current that was perceived to be tolerable (Abdellaoui 2011; Akar 2017; Dang 2011; Giavedoni 2012; Latimer 2013; Neder 2002; Tardif 2015; Tasdemir 2015; Vieira 2014; Vivodtzev 2006; Vivodtzev 2012). One study described setting an intensity that elicited a muscle contraction, and increasing by 5 mA per week (Bourjeily‐Habr 2002), and another study described setting the intensity to produce a muscular contraction equivalent to 15% to 25% of force generated during a maximum voluntary contraction (Maddocks 2016). Waveforms were most commonly symmetric or biphasic (or both) (Abdellaoui 2011; Akar 2017; Akinlabi 2013; Dang 2011; Giavedoni 2012; Kucio 2016; Latimer 2013; Neder 2002; Tasdemir 2015; Vieira 2014; Vivodtzev 2006; Vivodtzev 2012; Zanotti 2003). Regarding frequency, nine studies stimulated using 50 Hz (Akar 2017; Bourjeily‐Habr 2002; Giavedoni 2012; Latimer 2013; Maddocks 2016; Neder 2002; Tasdemir 2015; Vivodtzev 2012). Other studies reported using frequencies that ranged between 8 Hz and 45 Hz (Dang 2011), 10 Hz and 50 Hz (Akinlabi 2013), 5 Hz and 35 Hz (Vivodtzev 2006), 8 Hz and 35 Hz (Zanotti 2003), or 35 Hz (Abdellaoui 2011; Kucio 2016; Tardif 2015). Regarding duration, most studies stimulated once or twice a day for 30 to 60 minutes on four to seven days per week for four to eight weeks (Abdellaoui 2011; Latimer 2013; Maddocks 2016; Neder 2002; Tardif 2015; Vieira 2014; Vivodtzev 2006; Vivodtzev 2012; Zanotti 2003).

Exercise programmes

For the four studies that were conducted in an ICU, high dependency area or inpatient rehabilitation facility, and compared the effect of NMES plus conventional exercise training versus conventional exercise training alone, exercise training comprised active movement, active‐assisted movement or passive range of motion if the participant was unable to perform active movement through full range (Abdellaoui 2011; Akar 2017; Vivodtzev 2006; Zanotti 2003). One study described a programme that also facilitated participants to walk on a treadmill and use light arm weights once able (Vivodtzev 2006). The one study that was conducted in participants who were hospitalised (but clinically stable), and compared the effect of NMES plus conventional exercise training versus conventional exercise training alone, offered breathing exercises together with treadmill walking and resistance exercises (Kucio 2016). For the four studies that were conducted at home or in a rehabilitation or outpatient centre, and compared the effect of NMES plus conventional exercise training versus conventional exercise training alone, exercise training was described as low intensity symptom‐limited exercise (Akinlabi 2013), or usual exercise training/pulmonary rehabilitation (Dang 2011; Tardif 2015; Tasdemir 2015).

Outcome measures

Regarding the assessment of peripheral muscle force, two studies assessed quadriceps force used an isokinetic chair‐mounted dynamometer (Bourjeily‐Habr 2002; Neder 2002), and six studies assessed quadriceps force using a strain gauge or digital load cell that was fixed to a chair or rig (Dang 2011; Giavedoni 2012; Latimer 2013; Maddocks 2016; Vivodtzev 2006; Vivodtzev 2012). For the one study that measured quadriceps force during both a maximal voluntary isometric contraction and as twitch force in response to supramaximal femoral nerve stimulation (Maddocks 2016), the former, but not the latter measure was used in a meta‐analysis. One study assessed quadriceps force using a device that appeared to be hanging scale (Abdellaoui 2011), and one measured the one‐repetition maximum (Tasdemir 2015). Two studies described performing manual muscle testing of the 'peripheral muscles' or 'lower extremity muscles,' and although it was not clear which muscles were included in this assessment, it seemed likely that this assessment would have included quadriceps as both studies stimulated this muscle (Akar 2017; Zanotti 2003).

Three studies reported the assessment of quadriceps endurance. One study described a fatigue index in which high values were indicative of worse endurance (Neder 2002). Two studies described muscle endurance as time to fatigue during a given task, in which high values were indicative of better endurance (Dang 2011; Vivodtzev 2012). However, one study provided incomplete data on this outcome (Dang 2011), and therefore neither a meta‐analysis nor narrative discussion of these data was possible. One study reported collecting measures of quadriceps endurance, but these measures were of functional performance, such as squat tests in which the participant was required to perform as many squats as possible in 30 seconds (Tasdemir 2015). Therefore, neither a meta‐analysis nor narrative discussion of these data were undertaken.

Five studies reported the assessment of thigh muscle size (Latimer 2013; Maddocks 2016; Vieira 2014; Vivodtzev 2006; Vivodtzev 2012). Maddocks 2016 obtained measures of rectus femoris cross‐sectional area by ultrasound and Vivodtzev 2012 obtained measures of mid‐thigh cross‐sectional area by computed tomography. Latimer 2013 obtained measures of thigh muscle mass by dual‐energy X‐ray absorptiometry (DEXA) and Vieira 2014 and Vivodtzev 2006 obtained measures of thigh circumference via anthropometry.

We collected mortality data as part of our assessment of serious adverse events. Twelve studies contributed mortality data (Abdellaoui 2011; Akinlabi 2013; Bourjeily‐Habr 2002; Dang 2011; Kucio 2016; Maddocks 2016; Neder 2002; Tardif 2015; Tasdemir 2015; Vieira 2014; Vivodtzev 2012; Zanotti 2003 ). For minor adverse events related specifically to the stimulation itself, all but five studies reported data (Akar 2017; Giavedoni 2012; Kucio 2016; Vieira 2014; Vivodtzev 2006).

The most common measure of assessment of exercise capacity was the 6MWD (Abdellaoui 2011; Akinlabi 2013; Dang 2011; Kucio 2016; Maddocks 2016; Tardif 2015; Vieira 2014; Vivodtzev 2006). Other field‐based walking tests were less common, such as the incremental shuttle walk test (ISWT) (Bourjeily‐Habr 2002; Tasdemir 2015), and ESWT (Tasdemir 2015; Vivodtzev 2012). Measures of exercise capacity also comprised peak rate oxygen consumption (VO2peak) expressed as litres per minute (Neder 2002; Vivodtzev 2012), millilitres per minute (Bourjeily‐Habr 2002; Vieira 2014), or millilitres per kilogram per minute (Dang 2011). However, one study that reported on VO2peak could not be included in the meta‐analyses (due to differences in the units of measurement) and narrative discussion was not possible as the data that were provided were incomplete (Dang 2011). Four studies expressed exercise capacity as peak power (Bourjeily‐Habr 2002; Dang 2011; Neder 2002; Tardif 2015), and two studies expressed time to symptom limitation cycling at a constant submaximal intensity (Neder 2002; Vieira 2014). However, two studies that reported peak power and compared NMES plus conventional exercise training with conventional exercise training alone provided incomplete data (Dang 2011; Tardif 2015). Therefore, neither a meta‐analysis nor a narrative discussion of these data was possible (Dang 2011; Tardif 2015).

Two studies reported functional performance giving the time required for the participants in both groups to achieve specific mobility milestones, such as sitting out of bed (Akar 2017; Zanotti 2003).

Six studies assessed symptoms and reported dyspnoea at the end of an exercise test or at iso‐time during an exercise test using the Borg 0 to 10 scale (Maddocks 2016; Neder 2002Tasdemir 2015; Vieira 2014; Vivodtzev 2006; Vivodtzev 2012). Five studies reported leg fatigue or leg effort at the end of an exercise test using the Borg 0 to 10 scale (Maddocks 2016; Neder 2002; Tasdemir 2015; Vieira 2014; Vivodtzev 2012), and one study reported general fatigue during daily life using the Fatigue Severity Scale (Tasdemir 2015). However, Maddocks 2016 reported dyspnoea and leg fatigue on completion of the 6MWT performed at baseline only (i.e. no postintervention period data reported) and therefore neither a meta‐analysis nor narrative discussion of these data was possible. Three studies reported dyspnoea during daily life using the dyspnoea domain of the Chronic Respiratory Disease Questionnaire (CRDQ) (Dang 2011; Maddocks 2016; Neder 2002), and one study used the Maugeri Foundation Respiratory Failure questionnaire (MRF‐28) (Vivodtzev 2006). However, one study that reported dyspnoea during daily life using the CRDQ presented these data at baseline only (i.e. no postintervention period data reported) and therefore neither a meta‐analysis nor narrative discussion of these data was possible (Maddocks 2016). Although two studies that compared NMES plus conventional exercise training with conventional exercise training alone reported dyspnoea during daily life (Dang 2011; Vivodtzev 2006), Vivodtzev 2006 did not report data in a way that could be included in a meta‐analysis and therefore a meta‐analysis for this outcome was not possible. Grades from the modified Medical Research Council Scale were not included in the assessment of dyspnoea, as this scale assesses functional limitation resulting from dyspnoea rather than the severity of dyspnoea itself.

Regarding the assessment of HRQoL, five studies used the St George's Respiratory Questionnaire (SGRQ) in which high values represented worse HRQoL (Akinlabi 2013; Maddocks 2016; Tardif 2015; Tasdemir 2015; Vieira 2014), three used the CRDQ in which high values represented better HRQoL (Dang 2011; Maddocks 2016; Neder 2002), and one used the MRF‐28 in which high values represented worse HRQoL (Vivodtzev 2006). However, one study did not provide data on total CRDQ scores and therefore neither a meta‐analysis nor narrative discussion of these data was possible (Neder 2002). As one study reported HRQoL using both the SGRQ and CRDQ, we used only data collected using the SGRQ in the meta‐analysis (Maddocks 2016).

Excluded studies

After the removal of duplicates and clinical trial registrations, we excluded 40 studies (56 records) with reasons provided in the Characteristics of excluded studies table. Common reasons for exclusion related to the: use of a cross‐over study design; provision of magnetic stimulation; stimulation of muscles that were not peripheral limb muscles; application of electrical stimulation as acu‐transcutaneous electrical nerve stimulation (acu‐TENS); lack of a suitable control group) or insufficient proportion of participants with COPD.

Risk of bias in included studies

See Figure 2 and Figure 3 for a summary of the risk of bias for the studies included in this review.


Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.


Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Allocation

Although all studies reported that participants were randomised to groups, 12 studies did not describe the method used to develop the randomisation sequence and we judged these studies at unclear risk of bias (Akar 2017; Bourjeily‐Habr 2002; Dolmage 2016; Giavedoni 2012; Gigliotti 2004; Kucio 2016; Neder 2002; Tardif 2015; Vivodtzev 2006; Vivodtzev 2012; Zanotti 2003; Zanotti 2010). We judged only studies that described concealment of the randomisation sequence as being at low risk of this bias (Abdellaoui 2011; Akar 2017; Akinlabi 2013; Dang 2011; Maddocks 2016; Tasdemir 2015).

Blinding

Eight studies utilised sham stimulation in the control group and we judged these at low risk of performance bias (Abdellaoui 2011; Bourjeily‐Habr 2002; Dolmage 2016; Maddocks 2016; Tasdemir 2015; Vieira 2014; Vivodtzev 2012; Zanotti 2010). Only one study reported using a blinded assessor to collect all outcome measures and therefore we judged this at low of risk detection bias (Maddocks 2016). Sixteen studies did not describe blinding procedures or used a blinded assessor to collect some, but not all, outcomes, and we judged these studies at unclear risk of bias (Akar 2017; Bourjeily‐Habr 2002; Dang 2011; Dolmage 2016; Giavedoni 2012; Gigliotti 2004; Kucio 2016; Latimer 2013; Neder 2002; Tardif 2015; Tasdemir 2015; Vieira 2014; Vivodtzev 2006; Vivodtzev 2012; Zanotti 2003; Zanotti 2010). We judged two studies that specifically stated that the outcome assessors were not blinded to group allocation as being at high risk of bias (Abdellaoui 2011; Akinlabi 2013).

Incomplete outcome data

Eleven studies provided insufficient information regarding loss to follow‐up and so we judged these studies at unclear risk of bias (Akar 2017; Dang 2011; Dolmage 2016; Giavedoni 2012; Gigliotti 2004; Latimer 2013; Neder 2002; Tardif 2015; Vivodtzev 2006; Zanotti 2003; Zanotti 2010). All other studies reported minimal loss to follow‐up and so we judged these at low risk of bias (Abdellaoui 2011; Akinlabi 2013; Bourjeily‐Habr 2002; Kucio 2016; Maddocks 2016; Tasdemir 2015; Vieira 2014; Vivodtzev 2012).

Selective reporting

We judged the 12 studies that were published without having registered a study protocol as being at an unclear risk of bias (Akar 2017; Akinlabi 2013; Bourjeily‐Habr 2002; Dang 2011; Dolmage 2016; Giavedoni 2012; Gigliotti 2004; Kucio 2016; Neder 2002; Tardif 2015; Vivodtzev 2006; Zanotti 2003). We judged studies that were reported in a way that was generally consistent with a previously registered study protocol at low risk of bias (Abdellaoui 2011; Maddocks 2016; Vivodtzev 2012; Zanotti 2010). We judged studies that were reported in a way that was inconsistent with a previously registered study protocol as being a high risk of bias (Latimer 2013; Tasdemir 2015; Vieira 2014).

Other potential sources of bias

Five studies had a high proportion of men (Abdellaoui 2011; Kucio 2016; Tardif 2015; Tasdemir 2015; Vieira 2014), which may have increased the likelihood of a positive result as men have been demonstrated to tolerate high levels of stimulation when compared with women (Giavedoni 2012; Maffiuletti 2008), and gains in response to NMES appear to be dependent on the ability for participants to tolerate progressively higher current intensities (Vivodtzev 2012). Therefore we judged these at high risk of bias (Abdellaoui 2011; Kucio 2016; Tardif 2015; Tasdemir 2015; Vieira 2014). Seven studies were published in abstract form only (Akinlabi 2013; Dang 2011; Dolmage 2016; Gigliotti 2004; Latimer 2013; Tardif 2015; Zanotti 2010). Although additional information was obtained from the authors of four of these studies (Akinlabi 2013; Dang 2011; Latimer 2013; Tardif 2015), we judged these at unclear or high risk of 'other' bias. Regarding other potential sources of error, one study reported change scores as the difference in medians (not means) and the inclusion of these data in the meta‐analyses may have introduced error to the estimates of the effect (Akinlabi 2013).

Effects of interventions

See: Summary of findings for the main comparison NMES compared to usual care (with or without sham NMES) for COPD; Summary of findings 2 NMES and exercise compared to exercise (with or without sham NMES) for COPD

Primary outcomes

Peripheral muscle force

Six studies compared NMES with usual care and reported on measures of quadriceps muscle force (Bourjeily‐Habr 2002; Giavedoni 2012; Latimer 2013; Maddocks 2016; Neder 2002; Vivodtzev 2012). Meta‐analysis of these studies demonstrated a significant effect, however, the CIs were wide (SMD 0.34, 95% CI 0.02 to 0.65; participants = 159; low‐quality evidence; Analysis 1.1; Figure 4). One study included in this meta‐analysis also assessed quadriceps twitch force elicited in response to stimulation of the femoral nerve and demonstrated no significant between‐group difference (Maddocks 2016). As the meta‐analysis included the two studies that randomly assigned one leg to receive NMES and the other leg to receive control (Giavedoni 2012; Latimer 2013), we conducted a sensitivity analysis that excluded these studies. For this sensitivity analysis, the SMD from the remaining four studies was 0.39 (95% CI ‐0.00 to 0.78) (Bourjeily‐Habr 2002; Maddocks 2016; Neder 2002; Vivodtzev 2012). Regarding subgroup analyses based on whether or not the participants were clinically stable at the time of recruitment, of the six studies that compared NMES with usual care, only one recruited participants during a period of exacerbation (Giavedoni 2012). Therefore, rather than performing subgroup analyses based on the clinical stability of participants at the time of recruitment, we undertook a sensitivity analysis that excluded the study that recruited people during a period of exacerbation. The SMD for this subgroup analysis that included only participants with COPD who recruited during a period of clinical stability was 0.34 (95% CI 0.00 to 0.68) (Bourjeily‐Habr 2002; Latimer 2013; Maddocks 2016; Neder 2002; Vivodtzev 2012).


Forest plot of comparison: 1 Neuromuscular electrostimulation (NMES) versus usual care, outcome: 1.1 Peripheral muscle force.

Forest plot of comparison: 1 Neuromuscular electrostimulation (NMES) versus usual care, outcome: 1.1 Peripheral muscle force.

One study reported a significant increase in hamstring force following NMES that was greater than any seen in the control group (Bourjeily‐Habr 2002). One additional study, published as an abstract with a small number of participants, that could not be included in the meta‐analysis, compared the effect of two NMES training protocols on quadriceps force (Dolmage 2016). This study suggested that the gains in muscle force may be greater following an NMES training programme designed to increase strength (i.e. high‐frequency, low‐duty cycle) when compared with an NMES training protocol designed to increase endurance (i.e. low ‐frequency, high‐duty cycle) (Dolmage 2016). There were insufficient studies to undertake planned subgroup analyses based on stimulation frequency, disease severity, method used to assess muscle force or number of training sessions.

Six studies compared NMES plus conventional exercise training with conventional exercise training alone and reported measures of quadriceps muscle force (Abdellaoui 2011; Dang 2011; Tasdemir 2015; Vivodtzev 2006), or used manual muscle testing to report on peripheral muscle strength (which was likely to include measures of quadriceps muscle force) (Akar 2017; Zanotti 2003). However, data from two studies reported data as median and interquartile range or minimum and maximum values, and therefore were not included in the meta‐analyses (Abdellaoui 2011; Akar 2017). Meta‐analysis of the remaining four studies produced an uncertain effect with an SMD of 0.47 (95% CI ‐0.10 to 1.04; participants = 84; very low‐quality evidence; Analysis 2.1; Figure 5). Regarding the subgroup analyses based on whether or not the method used to measure muscle force was deemed to be robust, two studies used robust methods (Dang 2011; Vivodtzev 2006), and the SMD for these studies was 0.44 (95% CI ‐0.25 to 1.14; participants = 33) and two studies used less robust methods (Tasdemir 2015; Zanotti 2003), and the SMD for these studies was 0.53 (95% CI ‐0.74 to 1.80; participants = 51; Analysis 2.2; Figure 6). The SMD for these subgroups was not different (Chi2 = 0.01; P = 0.91). Only the analysis for muscle force assessed using less robust methods had high statistical heterogeneity (I2 = 79%). Regarding subgroup analyses based on the minimum number of training sessions, of the four studies, only one completed fewer than 10 sessions in four weeks (Tasdemir 2015). Therefore, rather than performing a subgroup analysis based on the minimum number of training sessions, we undertook a sensitivity analysis that excluded the study where participants completed fewer than 10 sessions over four weeks. For this sensitivity analysis, the SMD from the remaining three studies was 0.73 (95% CI 0.19 to 1.28; participants = 57; Analysis 2.3) (Dang 2011; Vivodtzev 2006; Zanotti 2003). One study also undertook manual muscle testing of the upper limbs; however, it was unclear whether the improvement in this measure was different between the groups (Akar 2017). There were insufficient studies to undertake planned subgroup analyses based on clinical stability at the time of recruitment, stimulation frequency or disease severity.


Forest plot of comparison: 2 Neuromuscular electrostimulation (NMES) plus exercise versus exercise only, outcome: 2.1 Peripheral muscle force.

Forest plot of comparison: 2 Neuromuscular electrostimulation (NMES) plus exercise versus exercise only, outcome: 2.1 Peripheral muscle force.


Forest plot of comparison: 2 Neuromuscular electrostimulation (NMES) plus exercise versus exercise only, outcome: 2.2 Peripheral muscle force with subgroups based on methods used to assess muscle force.

Forest plot of comparison: 2 Neuromuscular electrostimulation (NMES) plus exercise versus exercise only, outcome: 2.2 Peripheral muscle force with subgroups based on methods used to assess muscle force.

Peripheral muscle endurance/fatigability

Two studies compared NMES with usual care, and reported on measures of endurance of the quadriceps (Neder 2002; Vivodtzev 2012). Meta‐analysis of these studies demonstrated a significant effect in favour of NMES (SMD 1.36, 95% CI 0.59 to 2.12; participants = 35; low‐quality evidence; Analysis 1.2). One additional study, published as an abstract with a small numbers of participants, that could not be included in the meta‐analysis, compared the effect of two NMES training protocols on quadriceps endurance (Dolmage 2016). This study suggested that the gains in endurance may have been greater following an NMES training programme designed to increase endurance (i.e. low‐frequency, high‐duty cycle) when compared with an NMES training protocol designed the increase strength (i.e. high‐frequency, low‐duty cycle) (Dolmage 2016). There were insufficient studies to undertake planned subgroup analyses based on clinical stability at the time of recruitment, stimulation frequency, disease severity or the number of training sessions.

No studies compared NMES plus conventional exercise training with conventional exercise training alone, and reported on measures of quadriceps endurance.

Thigh muscle size

Four studies compared NMES with usual care, and reported on measures of thigh muscle size (Latimer 2013; Maddocks 2016; Vieira 2014; Vivodtzev 2012). Meta‐analysis of these studies produced an uncertain effect (SMD 0.25, 95% CI ‐0.11 to 0.61; participants = 124; low‐quality evidence; Analysis 1.3). As this analysis included the one study that randomly assigned one leg to receive NMES and the other leg to receive control (Latimer 2013), we conducted a sensitivity analysis that excluded this study. For this sensitivity analysis, the SMD from the remaining three studies was 0.32 (95% CI ‐0.09 to 0.74; participants = 92) (Maddocks 2016; Vieira 2014; Vivodtzev 2012). There were insufficient studies to undertake planned subgroup analyses based on clinical stability of the participants at the time of recruitment, stimulation frequency, disease severity or the number of training sessions.

The one study that compared NMES plus conventional exercise training with conventional exercise training alone, and reported on measures of thigh circumference demonstrated no between‐group difference in this outcome (Vivodtzev 2006).

Serious adverse events

Although six studies compared NMES with usual care, and reported data on mortality (Bourjeily‐Habr 2002; Latimer 2013; Maddocks 2016; Neder 2002; Vieira 2014; Vivodtzev 2012), we excluded data from the study that randomly assigned one leg to receive NMES and the other leg to receive control (Latimer 2013). Meta‐analysis of the remaining five studies demonstrated no risk difference between groups (RD ‐0.02, 95% CI ‐0.08 to 0.05; participants = 131; Analysis 1.4). These studies were undertaken in participants who were clinically stable at the time of recruitment.

Seven studies compared NMES plus conventional exercise training with conventional exercise training alone, and provided information on mortality (Abdellaoui 2011; Akinlabi 2013; Dang 2011; Kucio 2016; Tardif 2015; Tasdemir 2015; Zanotti 2003). Meta‐analysis of these studies demonstrated no risk difference between groups (RD 0.00, 95% CI ‐0.05 to 0.05; participants = 183; Analysis 2.4).

Secondary outcomes

Exercise capacity

Two studies compared NMES with usual care, and reported on measures of 6MWD (Maddocks 2016; Vieira 2014). Meta‐analysis of these studies demonstrated a significant effect (MD 39.26 m, 95% CI 16.31 to 62.22; low‐quality evidence; participants = 72; Analysis 1.5). Both studies were undertaken in participants who were clinically stable at the time of recruitment. There were insufficient studies to undertake planned subgroup analyses for the effect on 6MWD based on clinical stability of the participants at the time of recruitment, stimulation frequency, disease severity or the number of training sessions. The one study that reported on measures of incremental shuttle walk distance (ISWD) demonstrated a significant between‐group increase in favour of NMES (Bourjeily‐Habr 2002). Four studies reported on measures of VO2peak (Bourjeily‐Habr 2002; Neder 2002; Vieira 2014; Vivodtzev 2012), and meta‐analysis of these studies demonstrated a significant effect in favour of NMES (MD 0.10 L/min, 95% CI 0.00 to 0.19; participants = 73; Analysis 1.6). These studies were undertaken in participants who were clinically stable at the time of recruitment. There were insufficient studies to undertake planned subgroup analyses for the effect on VO2peak based on clinical stability of the participants at the time of recruitment, stimulation frequency, disease severity or the number of training sessions. Two studies reported on measures of peak power (Bourjeily‐Habr 2002; Neder 2002), and meta‐analysis of these studies produced an uncertain effect (MD 5.77 W, 95% CI ‐6.00 to 17.53; participants = 33; Analysis 1.7). Both studies were undertaken in participants who were clinically stable at the time of recruitment. There were insufficient studies to undertake planned subgroup analyses for the effect on peak power based on clinical stability of the participants at the time of recruitment, stimulation frequency, disease severity or the number of training sessions. Three studies reported on endurance time during a constant power test on a bike (Neder 2002; Vieira 2014), or on the ESWT (Vivodtzev 2012), and meta‐analysis of these studies demonstrated a significant effect (MD 3.62 minutes, 95% CI 2.33 to 4.91; participants = 55; Analysis 1.8). These studies were undertaken in participants who were clinically stable at the time of recruitment. There were insufficient studies to undertake planned subgroup analyses for the effect on endurance time based on clinical stability of the participants at the time of recruitment, stimulation frequency, disease severity or the number of training sessions.

Six studies compared NMES plus conventional exercise training with conventional exercise training alone, and reported on measures of 6MWD (Abdellaoui 2011; Akinlabi 2013; Dang 2011; Kucio 2016; Tardif 2015; Vivodtzev 2006). Meta‐analysis of these studies demonstrated a significant effect (MD 25.87 m, 95% CI 1.06 to 50.69; participants = 138; very low‐quality evidence; Analysis 2.5). Regarding subgroup analyses based on whether or not the participants were clinically stable at the time of recruitment, of the six studies that compared NMES plus conventional exercise training with conventional exercise training alone, only one recruited participants during a period of exacerbation (Abdellaoui 2011). Therefore, rather than perform a subgroup analysis based on clinical stability, we undertook a sensitivity analysis that excluded the study that recruited participants during a period of exacerbation. The MD for this meta‐analysis that included only people with COPD who were clinically stable at the time of recruitment was 17.80 m (95% CI ‐6.81 to 42.41; participants = 123) (Akinlabi 2013; Dang 2011; Kucio 2016; Tardif 2015; Vivodtzev 2006). Regarding subgroup analyses based on the minimum number of training sessions, of the six studies, only one completed fewer than 10 sessions in four weeks (Akinlabi 2013). Therefore, rather than performing a subgroup analysis based on the minimum number of training sessions, we undertook a sensitivity analysis that excluded the study in which participants completed fewer than 10 sessions over four weeks. For this sensitivity analysis, the MD from the remaining five studies was 25.86 m (95% CI ‐3.17 to 54.89; participants = 128; Analysis 2.6) (Abdellaoui 2011; Dang 2011; Kucio 2016; Tardif 2015; Vivodtzev 2006). There were insufficient studies to undertake planned subgroup analyses for the effect on 6MWD based on stimulation frequency or disease severity. The one study that reported on measures of exercise capacity expressed as ISWD and performance on the ESWT demonstrated a significant between‐group difference in favour of NMES plus conventional exercise training on ISWD, but not performance on the ESWT (expressed in seconds) (Tasdemir 2015).

Functional performance

None of the studies comparing NMES with usual care reported on measures of functional performance.

Two studies compared NMES plus conventional exercise training with conventional exercise training alone (Akar 2017; Zanotti 2003), and reported on the same measure of functional performance; number of days between randomisation and when the participant first transferred out of bed. Meta‐analysis of these studies demonstrated a significant effect on when the participant first transferred out of bed in favour of NMES plus conventional exercise training (MD ‐4.98 days, 95% CI ‐8.55 to ‐1.41; participants = 44; very low‐quality evidence; Analysis 2.7). Although both studies included in this meta‐analysis reported the same direction of effect, this analysis had high statistical heterogeneity (I2 = 60%). One of these studies was undertaken in participants who were clinically stable at the time of recruitment (Zanotti 2003), and the other was undertaken in participants who were experiencing an exacerbation at the time of recruitment (Akar 2017).

Symptoms of dyspnoea and fatigue

Three studies compared NMES with usual care, and reported on measures of dyspnoea reported on completion of a symptom‐limited exercise test (Neder 2002; Vieira 2014; Vivodtzev 2012). Meta‐analysis of these studies produced an uncertain effect (MD ‐1.03 units, 95% CI ‐2.13 to 0.06; participants = 55; very low‐quality evidence; Analysis 1.9). This analysis had high statistical heterogeneity (I2 = 59%). All studies were undertaken in participants who were clinically stable at the time of recruitment. The one study that reported on dyspnoea at iso‐time during the ESWT demonstrated no between‐group difference (Vivodtzev 2012). The one study that reported on measures of dyspnoea during daily life using the CRDQ demonstrated a significant between‐group difference in favour of NMES (Neder 2002). Three studies compared NMES with usual care, and reported on measures of leg fatigue reported on completion of an exercise test (Neder 2002; Vieira 2014; Vivodtzev 2006). Meta‐analysis of these studies demonstrated a significant effect (MD ‐1.12 units, 95% CI ‐1.81 to ‐0.43; participants = 55; Analysis 1.10). These studies were undertaken in participants who were clinically stable at the time of recruitment.

Two studies compared NMES plus conventional exercise training with conventional exercise training alone (Tasdemir 2015; Vivodtzev 2006), and reported on measures of dyspnoea reported on completion of an exercise test. Meta‐analysis of these studies produced an uncertain effect (MD ‐0.44 units, 95% CI ‐2.27 to 1.38; participants = 44; very low‐quality evidence; Analysis 2.8). This analysis had high statistical heterogeneity (I2 = 69%). Both studies were undertaken in participants who were clinically stable at the time of recruitment. Two studies compared NMES plus conventional exercise training with conventional exercise training alone on measures of dyspnoea during daily life (Dang 2011; Vivodtzev 2006). However, for one study, it was unclear whether the improvement in this measure was different between the groups (Dang 2011), and the between‐group difference reported in the other study was of borderline significance (P = 0.05) (Vivodtzev 2006). The one study that compared NMES plus conventional exercise training with conventional exercise training alone and reported on measures of leg fatigue on completion of an exercise test and general fatigue during daily life using the Fatigue Severity Scale demonstrated no between‐group differences in either of these outcomes (Tasdemir 2015).

Health‐related quality of life

Two studies compared NMES with usual care, and reported on measures of HRQoL measured using the SGRQ (Maddocks 2016; Vieira 2014). Meta‐analysis of these studies produced an uncertain effect (MD ‐4.12 %points, 95% CI ‐12.60 to 4.35; participants = 72; very low‐quality evidence; Analysis 1.11). This analysis had high statistical heterogeneity (I2 = 74%). One of these studies also demonstrated no between‐group difference in HRQoL assessed using the CRDQ (Maddocks 2016). These studies were undertaken in participants who were clinically stable at the time of recruitment.

Of the five studies that compared NMES plus conventional exercise training with conventional exercise training alone and reported on measures of HRQoL, three used the SGRQ (Akinlabi 2013; Tardif 2015; Tasdemir 2015), one used the CRDQ (Dang 2011), and one used the MRF‐28 (Vivodtzev 2006). Data from one study was reported as median and minimum and maximum and therefore were not included in the meta‐analysis (Tasdemir 2015). Meta‐analysis of the remaining four studies produced an uncertain effect (SMD ‐0.56, 95% CI ‐1.27 to 0.15; participants = 95; very low‐quality evidence; Analysis 2.9). This analysis had high statistical heterogeneity (I2 = 55%). These studies were undertaken in participants who were clinically stable at the time of recruitment.

Minor adverse events

Five studies compared NMES with usual care, and reported data on minor adverse events related to the intervention (Bourjeily‐Habr 2002; Latimer 2013; Maddocks 2016; Neder 2002; Vivodtzev 2012). Meta‐analysis of these studies demonstrated no risk difference between groups; however, there was inconsistency between individual studies (RD 0.00, 95% CI ‐0.07 to 0.07; participants = 139; low‐quality evidence; Analysis 1.12).

Six studies compared NMES plus conventional exercise training with conventional exercise training alone and reported data on minor adverse events related to the intervention (Abdellaoui 2011; Akinlabi 2013; Dang 2011; Tardif 2015; Tasdemir 2015; Zanotti 2003). Meta‐analysis of these studies demonstrated no risk difference between groups (RD 0.00, 95% CI ‐0.05 to 0.05; participants = 144; low‐quality evidence; Analysis 2.10). Of the six studies that compared NMES plus conventional exercise training with conventional exercise training alone, only one recruited participants during a period of exacerbation (Abdellaoui 2011).

Discussion

available in

Summary of main results

This review demonstrated an increase in quadriceps force following a programme of NMES applied in isolation, with an SMD of 0.34 (95% CI 0.02 to 0.65), suggesting a small to moderate effect (Cohen 1988). In real terms, using data available in one study that reported changes in quadriceps force in kilograms (Maddocks 2016), an SMD of 0.34 was equivalent to a difference in force of 3.1 kg (from a baseline mean force of 23.1 kg). Sensitivity analyses had minimal influence on the size of the SMD.

There was no increase in peripheral muscle force for those studies that applied NMES plus conventional exercise training (SMD 0.47, 95% CI ‐0.10 to 1.04). Subgroup analyses suggested that the size of the SMD was not influenced by the method used to quantify peripheral muscle force. Sensitivity analyses suggested that the effect of NMES on peripheral muscle force may have been influenced by the training dose applied. This is because the removal of the one study (Tasdemir 2015), which provided fewer than 10 training sessions over four weeks, resulted in a significant increase in the SMD to 0.73 (95% CI 0.19 to 1.28).

This review demonstrated that a programme of NMES applied in isolation produced a large increase in quadriceps muscle endurance, but no change in thigh muscle size. There were insufficient data to undertake a meta‐analysis of studies that explored the effect of applying NMES plus conventional exercise training on peripheral muscle endurance or thigh muscle size.

Regarding adverse events, there was no risk difference for mortality for participants who received NMES either in isolation or together with conventional exercise training. For the studies that reported data on mortality, of the 314 participants, there was only one death and this occurred in a control group participant who did not receive NMES (Maddocks 2016).

Regarding exercise capacity, studies that applied NMES in isolation demonstrated a small increase of VO2peak that was of borderline significance (MD 0.10 L/min, 95% CI 0.00 to 0.19). However, these studies demonstrated an increase in 6MWD that was statistically significant and exceeded the threshold for clinical importance suggested by Holland 2010 (MD 39.26 m, 95% CI 16.31 to 62.22). Further, an increase was also noted in the time to symptom limitation exercising at a submaximal intensity (i.e. endurance time). For studies that applied NMES plus conventional exercise training, there was a small increase in 6MWD, which was equivalent to the threshold for clinical importance (MD 25.87 m, 95% CI 1.06 to 50.69). This effect on 6MWD was no longer significant when the study that recruited participants during a period of exacerbation was excluded from the meta‐analysis (Abdellaoui 2011).

Regarding functional performance, there were insufficient data to undertake a meta‐analysis of studies that explored the effect of applying NMES in isolation. Studies that applied NMES plus conventional exercise training in people who were profoundly debilitated (i.e. either in an ICU or a respiratory high dependency unit following a prolonged admission to an ICU), demonstrated a reduction in the time taken to first sit out of bed by 4.98 days (95% CI ‐8.55 to ‐1.41). However, confidence in this result was reduced due to the high level of heterogeneity in this analysis (I2 = 60%). In addition to the gains in peripheral muscle function, improvements in exercise capacity and functional performance following NMES may also relate to the possible systemic effects of this intervention, such as increased microcirculation and heart rate response (Gerovasili 2009), and contralateral leg muscle facilitation (Hortobágyi 1999). Regarding symptoms measured on completion of exercise testing, studies that applied NMES in isolation demonstrated no difference in the severity of dyspnoea (MD ‐1.03, 95% CI ‐2.13 to 0.06). However, this analysis had high statistical heterogeneity (I2 = 59%). These studies demonstrated a decrease in the severity of leg fatigue on completion of exercise testing (MD ‐1.12 units, 95% CI ‐1.81 to ‐0.43). For studies that applied NMES plus conventional exercise training, there was no evidence of a decrease in the severity of dyspnoea on completion of exercise testing (MD ‐0.44, 95% CI ‐2.27 to 1.38). This analysis had high statistical heterogeneity (I2 = 69%).

Regarding HRQoL, studies that applied NMES in isolation demonstrated no difference in HRQoL, measured using the SGRQ. This analysis had high statistical heterogeneity (I2 = 74%). Similarly, studies that applied NMES plus conventional exercise training demonstrated no difference in HRQoL, measured using the SGRQ, CRDQ and MRF‐28.

Regarding minor adverse events related to the tolerance of the NMES, there was no risk difference for NMES when applied in isolation or together with conventional exercise training. For the studies that reported minor adverse events, data were available on 283 participants. Of these, six participants who received NMES and four participants who received sham NMES reported minor events.

Many of the planned subgroup analyses were not possible due to the limited number of studies available for inclusion in this review.

Overall completeness and applicability of evidence

Studies included in this review were undertaken at single centres and recruited modest sample sizes (fewer than 30 per group). Of the 16 studies included in the meta‐analyses, four were published only in abstract form. Several studies provided NMES in the home with little, if any, supervision. Therefore, poor adherence with NMES may have dampened the estimate of the effect of this intervention. Nevertheless, in clinical practice, offering NMES in the home is likely to be the most feasible and inexpensive approach and the inclusion of studies that described home‐based NMES increases the likelihood that the results of this review reflect the 'real life' effects of the intervention. In contrast to earlier reviews, we separated those studies that explored the effect of NMES applied in isolation (i.e. versus usual care) and those that explore the effect of adding NMES to a programme of conventional exercise training. In this way, the results of this review will assist clinicians to appreciate the possible effects of NMES applied in isolation from other rehabilitation strategies, as well as offering it as an adjunct to conventional exercise training.

Quality of the evidence

Using the GRADE approach, the quality of the evidence for most outcomes was low or very low. This was due, at least in part, to the risk of bias, especially detection and performance bias in most studies. Of note, only one study described blinding procedures for both participants and outcome assessors for every outcome (Maddocks 2016). Although in studies of interventions such as NMES, it is not possible to blind the person administering the intervention, the use of sham stimulation in the control group is critical to reduce the risk of performance bias, especially considering most outcomes reported in these studies were effort‐dependent or participant‐reported. For many of the meta‐analyses undertaken in this review, data were combined across only two or three studies, and the results of these studies were inconsistent, resulting in low levels of precision for our estimate of the effect. For outcomes related to functional performance, symptoms and HRQoL, most meta‐analyses showed high levels of heterogeneity. Finally, it is possible that the results of this review were influenced by the over‐representation of men in five studies (Abdellaoui 2011; Kucio 2016; Tardif 2015; Tasdemir 2015; Vieira 2014). Earlier work has demonstrated that men tolerate high levels of stimulation when compared with women (Giavedoni 2012; Maffiuletti 2008), and this may optimise the gains made in response to NMES (Vivodtzev 2012).

Potential biases in the review process

It is possible that our estimate of the effect of NMES on peripheral muscle force was influenced by including the study that measured 'peripheral muscle strength' using manual muscle testing (Zanotti 2003). We included this study because this review planned, a priori, to explore the effect of NMES on peripheral muscle force. Further, although it was not clear which muscles were tested in this study, it seemed reasonable to assume that these assessments included quadriceps force, as this was the muscle that was stimulated. Finally, the stimulation protocols described in the included studies varied considerably. For example, the setting varied from home‐based studies to those undertaken in the ICU. The number of muscles stimulated ranged from just the quadriceps to three separate lower limb muscles. The frequency used for stimulation ranged from 35 Hz to 50 Hz. The exposure to stimulation ranged from twice a day to twice a week, for 30 to 60 minutes per session, over three to 10 weeks. There were insufficient studies to attempt to determine the most effective protocol. We were unable to contact the authors of some studies that were published as abstracts and therefore, could not include the data from these studies in the review.

Agreements and disagreements with other studies or reviews

Data demonstrating that NMES increased peripheral muscle force when applied in isolation were consistent with previous reviews in this area (Chen 2016; Jones 2016; Roig 2009). Although one review reported no effect of NMES on maximal quadriceps muscle force, the estimate of the effect was of similar magnitude of that reported in the current study (SMD 0.38) and was likely not to have reached statistical significance as this earlier review included fewer studies in the meta‐analysis (Pan 2014).

Our data demonstrating an increase in quadriceps endurance were consistent with the only previous report to extract data on this outcome (Jones 2016). Our result of no change in thigh muscle size was consistent with one previous study that described equivocal evidence for the effect of NMES on this outcome (Roig 2009). Nevertheless, it contrasts with another review that demonstrated an effect on muscle mass measured using ultrasound or computed tomography (Jones 2016). The reasons for this disparity appeared to relate to the fact that this earlier review analysed studies grouped according to the method used to quantify thigh muscle size and also included data from a study undertaken in adults with severe chronic heart failure (Quittan 2001). Also, in contrast with the current review which used only measures of SD at baseline in the calculation of the SMD, the earlier review used the SD of the within‐group change to calculate the SMD. This reduced the variability of the estimate of the SMD and increased the likelihood of a 'significant' result.

Regarding adverse events, data demonstrating no risk difference between groups in major or minor adverse events were consistent with earlier reports (Jones 2016; Roig 2009).

Consistent with our findings of the effect of NMES on exercise capacity, earlier reviews reported changes in some, but not all, measures (Jones 2016; Chen 2016). Although consistent with earlier reviews that demonstrated a significant increase in 6MWD (Chen 2016; Jones 2016), our data extended this finding by suggesting that the effect of NMES on 6MWD was lessened when this intervention was combined with conventional exercise training. One review reported a significant increase in walking distance that was larger than seen in the current review or a previous review (MD 47.55 m) (Roig 2009). However, the earlier review combined data on exercise capacity measured via the 6MWT and the ISWT (Roig 2009). One previous review reported no difference in 6MWD (Pan 2014), but included different and fewer studies than the other reviews. Regarding other measures of exercise capacity, in contrast with the current review, an earlier review demonstrated no increase in VO2peak (Jones 2016). The reason for this disparity related to the inclusion of different studies in the meta‐analyses. Specifically, the earlier review included data from a randomised cross‐over study that was excluded from the current review (Napolis 2006). Also, we included measures of VO2peak collected on completion of the ISWT (Vivodtzev 2012), because in people with COPD, the VO2peak achieved on completion of an ISWT is similar to that achieved on completion of a laboratory‐based cycle ergometry test (Hill 2012). Finally, our finding of an increase in endurance time is consistent with earlier work (Chen 2016).

No earlier review has explored the effect of NMES on functional outcomes and so we were unable to comment on similarities or differences regarding this result.

Regarding the effect on symptoms, our data suggested that NMES applied in isolation reduced the severity of leg fatigue at the end of an exercise test. Earlier work suggested that NMES reduced dyspnoea, but did not separate the studies that applied NMES in isolation from those that applied NMES plus conventional exercise training (Pan 2014). One earlier review did not undertake a meta‐analysis of data on symptoms, but commented that data on this outcome were equivocal (Jones 2016).

Regarding changes in HRQoL, our finding of no effect was consistent with an earlier meta‐analysis on this outcome (Chen 2016), and supported the conclusion of equivocal evidence based on a narrative summary of these data (Jones 2016).

We acknowledge that the study criteria for this review meant that we were unable to include data reported in one of the largest trials of NMES in people with COPD (Sillen 2014). As this study compared two stimulation protocols with a programme of resistance training, it did not have an appropriate control group to be considered for inclusion in this review.

Study flow diagram.
Figures and Tables -
Figure 1

Study flow diagram.

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Figures and Tables -
Figure 2

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figures and Tables -
Figure 3

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Forest plot of comparison: 1 Neuromuscular electrostimulation (NMES) versus usual care, outcome: 1.1 Peripheral muscle force.
Figures and Tables -
Figure 4

Forest plot of comparison: 1 Neuromuscular electrostimulation (NMES) versus usual care, outcome: 1.1 Peripheral muscle force.

Forest plot of comparison: 2 Neuromuscular electrostimulation (NMES) plus exercise versus exercise only, outcome: 2.1 Peripheral muscle force.
Figures and Tables -
Figure 5

Forest plot of comparison: 2 Neuromuscular electrostimulation (NMES) plus exercise versus exercise only, outcome: 2.1 Peripheral muscle force.

Forest plot of comparison: 2 Neuromuscular electrostimulation (NMES) plus exercise versus exercise only, outcome: 2.2 Peripheral muscle force with subgroups based on methods used to assess muscle force.
Figures and Tables -
Figure 6

Forest plot of comparison: 2 Neuromuscular electrostimulation (NMES) plus exercise versus exercise only, outcome: 2.2 Peripheral muscle force with subgroups based on methods used to assess muscle force.

Comparison 1 Neuromuscular electrostimulation (NMES) versus usual care, Outcome 1 Peripheral muscle force.
Figures and Tables -
Analysis 1.1

Comparison 1 Neuromuscular electrostimulation (NMES) versus usual care, Outcome 1 Peripheral muscle force.

Comparison 1 Neuromuscular electrostimulation (NMES) versus usual care, Outcome 2 Peripheral muscle endurance/fatigability.
Figures and Tables -
Analysis 1.2

Comparison 1 Neuromuscular electrostimulation (NMES) versus usual care, Outcome 2 Peripheral muscle endurance/fatigability.

Comparison 1 Neuromuscular electrostimulation (NMES) versus usual care, Outcome 3 Thigh muscle size.
Figures and Tables -
Analysis 1.3

Comparison 1 Neuromuscular electrostimulation (NMES) versus usual care, Outcome 3 Thigh muscle size.

Comparison 1 Neuromuscular electrostimulation (NMES) versus usual care, Outcome 4 Mortality.
Figures and Tables -
Analysis 1.4

Comparison 1 Neuromuscular electrostimulation (NMES) versus usual care, Outcome 4 Mortality.

Comparison 1 Neuromuscular electrostimulation (NMES) versus usual care, Outcome 5 Exercise capacity: 6‐minute walking distance (6MWD) (m).
Figures and Tables -
Analysis 1.5

Comparison 1 Neuromuscular electrostimulation (NMES) versus usual care, Outcome 5 Exercise capacity: 6‐minute walking distance (6MWD) (m).

Comparison 1 Neuromuscular electrostimulation (NMES) versus usual care, Outcome 6 Exercise capacity: VO2peak (L/min).
Figures and Tables -
Analysis 1.6

Comparison 1 Neuromuscular electrostimulation (NMES) versus usual care, Outcome 6 Exercise capacity: VO2peak (L/min).

Comparison 1 Neuromuscular electrostimulation (NMES) versus usual care, Outcome 7 Exercise capacity: peak power (W).
Figures and Tables -
Analysis 1.7

Comparison 1 Neuromuscular electrostimulation (NMES) versus usual care, Outcome 7 Exercise capacity: peak power (W).

Comparison 1 Neuromuscular electrostimulation (NMES) versus usual care, Outcome 8 Exercise capacity: endurance time (min).
Figures and Tables -
Analysis 1.8

Comparison 1 Neuromuscular electrostimulation (NMES) versus usual care, Outcome 8 Exercise capacity: endurance time (min).

Comparison 1 Neuromuscular electrostimulation (NMES) versus usual care, Outcome 9 Symptoms: dyspnoea reported at end exercise.
Figures and Tables -
Analysis 1.9

Comparison 1 Neuromuscular electrostimulation (NMES) versus usual care, Outcome 9 Symptoms: dyspnoea reported at end exercise.

Comparison 1 Neuromuscular electrostimulation (NMES) versus usual care, Outcome 10 Symptoms: leg fatigue reported at end exercise.
Figures and Tables -
Analysis 1.10

Comparison 1 Neuromuscular electrostimulation (NMES) versus usual care, Outcome 10 Symptoms: leg fatigue reported at end exercise.

Comparison 1 Neuromuscular electrostimulation (NMES) versus usual care, Outcome 11 Health‐related quality of life: SGRQ.
Figures and Tables -
Analysis 1.11

Comparison 1 Neuromuscular electrostimulation (NMES) versus usual care, Outcome 11 Health‐related quality of life: SGRQ.

Comparison 1 Neuromuscular electrostimulation (NMES) versus usual care, Outcome 12 Minor adverse events: related to intervention.
Figures and Tables -
Analysis 1.12

Comparison 1 Neuromuscular electrostimulation (NMES) versus usual care, Outcome 12 Minor adverse events: related to intervention.

Comparison 2 Neuromuscular electrostimulation (NMES) plus exercise versus exercise only, Outcome 1 Peripheral muscle force.
Figures and Tables -
Analysis 2.1

Comparison 2 Neuromuscular electrostimulation (NMES) plus exercise versus exercise only, Outcome 1 Peripheral muscle force.

Comparison 2 Neuromuscular electrostimulation (NMES) plus exercise versus exercise only, Outcome 2 Peripheral muscle force with subgroups based on methods used to assess muscle force.
Figures and Tables -
Analysis 2.2

Comparison 2 Neuromuscular electrostimulation (NMES) plus exercise versus exercise only, Outcome 2 Peripheral muscle force with subgroups based on methods used to assess muscle force.

Comparison 2 Neuromuscular electrostimulation (NMES) plus exercise versus exercise only, Outcome 3 Peripheral muscle force: sensitivity analysis.
Figures and Tables -
Analysis 2.3

Comparison 2 Neuromuscular electrostimulation (NMES) plus exercise versus exercise only, Outcome 3 Peripheral muscle force: sensitivity analysis.

Comparison 2 Neuromuscular electrostimulation (NMES) plus exercise versus exercise only, Outcome 4 Mortality.
Figures and Tables -
Analysis 2.4

Comparison 2 Neuromuscular electrostimulation (NMES) plus exercise versus exercise only, Outcome 4 Mortality.

Comparison 2 Neuromuscular electrostimulation (NMES) plus exercise versus exercise only, Outcome 5 Exercise capacity: 6‐minute walking distance (6MWD) (m).
Figures and Tables -
Analysis 2.5

Comparison 2 Neuromuscular electrostimulation (NMES) plus exercise versus exercise only, Outcome 5 Exercise capacity: 6‐minute walking distance (6MWD) (m).

Comparison 2 Neuromuscular electrostimulation (NMES) plus exercise versus exercise only, Outcome 6 Exercise capacity: 6MWD (m): sensitivity analysis.
Figures and Tables -
Analysis 2.6

Comparison 2 Neuromuscular electrostimulation (NMES) plus exercise versus exercise only, Outcome 6 Exercise capacity: 6MWD (m): sensitivity analysis.

Comparison 2 Neuromuscular electrostimulation (NMES) plus exercise versus exercise only, Outcome 7 Functional performance: days to first transfer out of bed.
Figures and Tables -
Analysis 2.7

Comparison 2 Neuromuscular electrostimulation (NMES) plus exercise versus exercise only, Outcome 7 Functional performance: days to first transfer out of bed.

Comparison 2 Neuromuscular electrostimulation (NMES) plus exercise versus exercise only, Outcome 8 Symptoms: dyspnoea reported at end exercise.
Figures and Tables -
Analysis 2.8

Comparison 2 Neuromuscular electrostimulation (NMES) plus exercise versus exercise only, Outcome 8 Symptoms: dyspnoea reported at end exercise.

Comparison 2 Neuromuscular electrostimulation (NMES) plus exercise versus exercise only, Outcome 9 Health‐related quality of life.
Figures and Tables -
Analysis 2.9

Comparison 2 Neuromuscular electrostimulation (NMES) plus exercise versus exercise only, Outcome 9 Health‐related quality of life.

Comparison 2 Neuromuscular electrostimulation (NMES) plus exercise versus exercise only, Outcome 10 Minor adverse events related to intervention.
Figures and Tables -
Analysis 2.10

Comparison 2 Neuromuscular electrostimulation (NMES) plus exercise versus exercise only, Outcome 10 Minor adverse events related to intervention.

Summary of findings for the main comparison. NMES compared to usual care (with or without sham NMES) for COPD

NMES compared to usual care (with or without sham NMES) for COPD

Patient or population: COPD

Setting: generally outpatient or home

Intervention: NMES

Comparison: usual care (with or without sham NMES)

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

№ of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Risk with usual care (with or without sham NMES)

Risk with NMES

Peripheral muscle force

assessed with: any method

SMD 0.34 SD higher
(0.02 higher to 0.65 higher)

159
(6 RCTs)

⊕⊕⊝⊝
Lowa

In real terms, using data available in 1 study that reported changes in quadriceps force in kg (Maddocks 2016), an SMD of 0.34 was equivalent to a difference in force of 3.1 kg (from a baseline mean force of 23.1 kg).

Peripheral muscle endurance/fatigability

assessed with: any method

SMD 1.36 SD higher
(0.59 higher to 2.12 higher)

35
(2 RCTs)

⊕⊕⊝⊝
Lowb

Thigh muscle size assessed with: any method

SMD 0.25 SD higher
(0.11 lower to 0.61 higher)

124
(4 RCTs)

⊕⊕⊝⊝
Lowc

Exercise capacity

assessed with: 6MWD (m)

The mean change in 6MWD in the control group ranged from ‐5.70 m to 0.80 m

MD 39.26 m more
(16.31 more to 62.22 more)

72
(2 RCTs)

⊕⊕⊝⊝
Lowd

Functional performance

assessed with: time (days) until first sit out of bed

None of the studies reported on functional performance.

Symptoms of dyspnoea reported on completion of an exercise test

assessed with: Borg score

The mean change in dyspnoea reported on completion of an exercise test ranged from ‐0.50 to 0.40

MD 1.03 less dyspnoea
(2.13 less to 0.06 more)

55
(3 RCTs)

⊕⊝⊝⊝
Very lowe

Health‐related quality of life

assessed with: SGRQ

The mean change in HRQoL ranged from ‐2.00 to 0.07

MD 4.12 better
(12.60 better to 4.35 worse)

72
(2 RCTs)

⊕⊝⊝⊝
Very lowf

Minor adverse events

assessed: related to intervention only (e.g. redness)

5970 per 100,000

0 per 100,000
(‐418 to 418)

RD 0.00
(‐0.07 to 0.07)

139
(5 RCTs)

⊕⊕⊝⊝
Lowg

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

6MWD: 6‐minute walk distance; CI: confidence interval; COPD: chronic obstructive pulmonary disease; MD: mean difference; NMES: neuromuscular electrical stimulation; RCT: randomised controlled trials; RD: risk difference; SD: standard deviation; SGRQ: Saint George's Respiratory Questionnaire; SMD: standardised mean difference.

GRADE Working Group grades of evidence
High quality: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low quality: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low quality: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

aDowngraded one level due to risk of bias (three studies did not use sham stimulation) and one level due to imprecision (wide confidence intervals).

bDowngraded one level due to risk of bias (one study did not use sham stimulation) and one level due to small number of studies available for analyses.

cDowngraded one level due to risk of bias (one study did not use sham stimulation) and one level due imprecision (wide confidence intervals).

dDowngraded one level due to small number of studies available for analyses and one level due imprecision (wide confidence intervals).

eDowngraded one level due to risk of bias (one study did not use sham stimulation), one level for imprecision (wide confidence intervals) and one level for inconsistency.

fDowngraded one level due to small number of studies available for analyses, one level for imprecision (wide confidence intervals) and one level due to inconsistent findings.

gDowngraded one level due to risk of bias (two studies did not use sham stimulation) and one level for inconsistent findings.

Figures and Tables -
Summary of findings for the main comparison. NMES compared to usual care (with or without sham NMES) for COPD
Summary of findings 2. NMES and exercise compared to exercise (with or without sham NMES) for COPD

NMES and exercise compared to exercise (with or without sham NMES) for COPD

Patient or population: COPD

Setting: intensive care unit, inpatient rehabilitation, outpatient or home

Intervention: NMES + exercise

Comparison: exercise (with or without sham NMES)

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

№ of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Risk with exercise (with or without sham NMES)

Risk with NMES and exercise

Peripheral muscle force

assessed with: any method

SMD 0.47 SD higher
(‐0.10 higher to 1.04 higher)

84
(4 RCTs)

⊕⊝⊝⊝
Very lowa

Peripheral muscle endurance/fatigability

assessed with: any method

None of the studies reported peripheral muscle endurance/fatigability.

Thigh muscle size assessed with: any method

None of the studies reported thigh muscle size.

Exercise capacity

assessed with: 6MWD (m)

The mean change in 6MWD ranged from 10.30 m to 94.00 m

MD 25.87 m more
(1.06 more to 50.69 more)

138
(6 RCTs)

⊕⊝⊝⊝
Very lowb

Functional performance

assessed with: time (days) until first sit out of bed

The mean time until first sit out of bed ranged from 12.60 to 14.33 days

MD 4.98 fewer days
(8.55 to 1.41 fewer)

44
(2 RCTs)

⊕⊝⊝⊝
Very lowc

Symptoms of dyspnoea reported on completion of an exercise test

assessed with: Borg score

The mean change in dyspnoea reported on completion of an exercise test ranged from ‐0.62 units to 1.00 units

MD 0.44 less dyspnoea
(2.27 less to 1.38 more)

44
(2 RCTs)

⊕⊝⊝⊝
Very lowd

Health‐related quality of life

assessed with: any validated questionnaire

SMD 0.56 SD better
(1.27 better to 0.15 worse)

122
(5 RCTs)

⊕⊝⊝⊝
Very lowe

Minor adverse events
assessed: related to intervention only (e.g. redness)

0 per 1000

0 per 1000
(0 to 0)

Not estimable

144
(6 RCTs)

⊕⊕⊝⊝

Lowf

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

6MWD: 6‐minute walk distance; CI: confidence interval;COPD: chronic obstructive pulmonary disease; MD: mean difference; NMES: neuromuscular electrical stimulation; RCT: randomised controlled trials; SD: standard deviation; SMD: standardised mean difference.

GRADE Working Group grades of evidence
High quality: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low quality: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low quality: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

aDowngraded one level due to risk of bias (three studies did not use sham stimulation), one level due to imprecision (wide confidence intervals) and one level due to inconsistent findings.

bDowngraded one level due to risk of bias (five studies did not use sham stimulation), one level due to imprecision (wide confidence intervals) and one level due to inconsistent findings.

cDowngraded one level due to risk of bias (neither study used sham stimulation), one level due imprecision (wide confidence intervals) and one level due to small number of studies available for analyses.

dDowngraded one level due to risk of bias (one study did not use sham stimulation), one level due imprecision (wide confidence intervals) and small number of studies available for analyses, and one level for inconsistent findings.

eDowngraded one level due to risk of bias (four studies did not use sham stimulation), one level for imprecision (wide confidence intervals) and one level for inconsistency.

fDowngraded one level due to risk of bias (four studies did not use sham stimulation) and one level for imprecision (wide confidence intervals).

Figures and Tables -
Summary of findings 2. NMES and exercise compared to exercise (with or without sham NMES) for COPD
Table 1. Characteristics of studies that contributed data to meta‐analyses (NMES versus usual care)

Study

Setting

Lower limb stimulation

Clinical stability

Dose

Frequency (Hz)

Intervention received by control group

Bourjeily‐Habr 2002

Outpatient

Bilateral quadriceps, hamstrings and calf

Stable

20 min per day, 3 days per week for 6 weeks at an intensity that elicited a muscle contraction, and increasing by 5 mA per week

50

Sham stimulation

Giavedoni 2012

Hospital ward then at home

Unilateral quadriceps

Acute exacerbation

30 min per day, once per day for 14 days at maximum tolerated current

50

Nil

Latimer 2013

Combination of supervised and unsupervised home training

Unilateral quadriceps

Stable

30 min per session,
5 times per week, for 6 weeks at maximum tolerated current

50

Nil

Maddocks 2016

Home

Bilateral quadriceps

Stable

30 min per day, 7 days per
week for 6 weeks with current set to elicit a contraction equivalent to 15‐25% of a maximum voluntary contraction

50

Sham stimulation

Neder 2002

First week as outpatient then home

Bilateral quadriceps

Stable

15 min (to each leg) in the first
week which increased to 30 min thereafter, for 5 days per week for 6 weeks at maximum tolerated current

50

Nil

Vieira 2014

Presumably home

Bilateral quadriceps

Stable

60 min per session, 2 times per day, 5 days per week, for 8 weeks at maximum tolerated current

50

Both groups received respiratory physical therapy (i.e. airway clearance) as indicated as well as stretching exercises for the upper limbs, lower limbs and back (control group also received sham stimulation).

Vivodtzev 2012

Home

Bilateral quadriceps and calf

Stable

60 minutes per session, 5 days per week for 6 weeks at maximum tolerated current

50

Sham stimulation

min: minute; NMES: neuromuscular electrostimulation.

Figures and Tables -
Table 1. Characteristics of studies that contributed data to meta‐analyses (NMES versus usual care)
Table 2. Characteristics of studies that contributed data to meta‐analyses (NMES + exercise versus exercise alone)

Study

Setting

Lower limb stimulation

Clinical stability

Dose

Frequency (Hz)

Exercise intervention received by control group

Abdellaoui 2011

Intensive care unit

Bilateral quadriceps and hamstrings

Acute exacerbation

1 hour per day, 5 days per week for 6 weeks at maximum tolerated current

35

Both groups received education (once per week) and daily active‐passive mobilisation (control group also received sham stimulation).

Akar 2017

Intensive care unit

Bilateral quadriceps

Respiratory failure

5 days per week (total of 20 sessions) at maximum tolerated current

50

Both groups received active exercise, which comprised active joint range of motion exercise for upper and lower limbs. Participants who could not manage active exercise received active‐assisted or passive range of motion exercise.

Akinlabi 2013

Home

Bilateral quadriceps and hamstrings

Stable

2 days per week for 8 weeks (total of 16 sessions)

10‐50

Low‐intensity symptom‐limited exercise

Dang 2011

Outpatient

Bilateral quadriceps

Stable

36 min, 3 sessions per week for 12 weeks (total of 36 sessions) at maximum tolerated current

8‐45

Usual respiratory rehabilitation (no other details given)

Kucio 2016

Inpatient rehabilitation

Bilateral quadriceps and calf

Stable

36 min, presumably 6 supervised
sessions per week for 3 weeks, intensity not specified

35

Both groups received breathing exercises, treadmill walking and resistance exercise.

Tardif 2015

Home

Bilateral quadriceps

Stable

Presumably 30 min per day, 5 days per week, presumably for 8 weeks at maximum tolerated current

35

Both groups received pulmonary rehabilitation.

Tasdemir 2015

Outpatient

Bilateral quadriceps

Stable

20 min, 2 days per week for 10 weeks at maximum tolerated current

50

Both groups received pulmonary rehabilitation (control group also received sham stimulation).

Vivodtzev 2006

Inpatient rehabilitation

Bilateral quadriceps

Stable, but shortly following acute illness

> 30 min per session, 4 times per week, for 4 weeks at maximum tolerated current

5‐35

Both groups received active limb exercises. The strongest participants also performed walking on a treadmill together with 5‐10 min of resistance arm exercises. They also completed health education sessions 1 day per week.

Zanotti 2003

Respiratory high dependency unit for inpatient rehabilitation

Bilateral quadriceps and gluteals

Stable, but shortly following acute illness

Up to 30 min per session, 2 times per day, 5 days per week for 4 weeks presumably at maximum tolerated current

8‐35

Both groups received rehabilitation that comprised active limb exercises.

min: minute; NMES: neuromuscular electrostimulation.

Figures and Tables -
Table 2. Characteristics of studies that contributed data to meta‐analyses (NMES + exercise versus exercise alone)
Comparison 1. Neuromuscular electrostimulation (NMES) versus usual care

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Peripheral muscle force Show forest plot

6

159

Std. Mean Difference (IV, Random, 95% CI)

0.34 [0.02, 0.65]

2 Peripheral muscle endurance/fatigability Show forest plot

2

35

Std. Mean Difference (IV, Random, 95% CI)

1.36 [0.59, 2.12]

3 Thigh muscle size Show forest plot

4

124

Std. Mean Difference (IV, Random, 95% CI)

0.25 [‐0.11, 0.61]

4 Mortality Show forest plot

5

131

Risk Difference (M‐H, Random, 95% CI)

‐0.02 [‐0.08, 0.05]

5 Exercise capacity: 6‐minute walking distance (6MWD) (m) Show forest plot

2

72

Mean Difference (IV, Random, 95% CI)

39.26 [16.31, 62.22]

6 Exercise capacity: VO2peak (L/min) Show forest plot

4

73

Mean Difference (IV, Random, 95% CI)

0.10 [0.00, 0.19]

7 Exercise capacity: peak power (W) Show forest plot

2

33

Mean Difference (IV, Random, 95% CI)

5.77 [‐4.00, 17.53]

8 Exercise capacity: endurance time (min) Show forest plot

3

55

Mean Difference (IV, Random, 95% CI)

3.62 [2.33, 4.91]

9 Symptoms: dyspnoea reported at end exercise Show forest plot

3

55

Mean Difference (IV, Random, 95% CI)

‐1.03 [‐2.13, 0.06]

10 Symptoms: leg fatigue reported at end exercise Show forest plot

3

55

Mean Difference (IV, Random, 95% CI)

‐1.12 [‐1.81, ‐0.43]

11 Health‐related quality of life: SGRQ Show forest plot

2

72

Mean Difference (IV, Random, 95% CI)

‐4.12 [‐12.60, 4.35]

12 Minor adverse events: related to intervention Show forest plot

5

139

Risk Difference (M‐H, Random, 95% CI)

0.00 [‐0.07, 0.07]

Figures and Tables -
Comparison 1. Neuromuscular electrostimulation (NMES) versus usual care
Comparison 2. Neuromuscular electrostimulation (NMES) plus exercise versus exercise only

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Peripheral muscle force Show forest plot

4

84

Std. Mean Difference (IV, Random, 95% CI)

0.47 [‐0.10, 1.04]

2 Peripheral muscle force with subgroups based on methods used to assess muscle force Show forest plot

4

84

Std. Mean Difference (IV, Random, 95% CI)

0.47 [‐0.10, 1.04]

2.1 Robust strength measure

2

33

Std. Mean Difference (IV, Random, 95% CI)

0.44 [‐0.25, 1.14]

2.2 Less robust strength measures

2

51

Std. Mean Difference (IV, Random, 95% CI)

0.53 [‐0.74, 1.80]

3 Peripheral muscle force: sensitivity analysis Show forest plot

3

57

Std. Mean Difference (IV, Random, 95% CI)

0.73 [0.19, 1.28]

4 Mortality Show forest plot

7

183

Risk Difference (M‐H, Random, 95% CI)

0.0 [‐0.05, 0.05]

5 Exercise capacity: 6‐minute walking distance (6MWD) (m) Show forest plot

6

138

Mean Difference (IV, Random, 95% CI)

25.87 [1.06, 50.69]

6 Exercise capacity: 6MWD (m): sensitivity analysis Show forest plot

5

128

Mean Difference (IV, Random, 95% CI)

25.86 [‐3.17, 54.89]

7 Functional performance: days to first transfer out of bed Show forest plot

2

44

Mean Difference (IV, Random, 95% CI)

‐4.98 [‐8.55, ‐1.41]

8 Symptoms: dyspnoea reported at end exercise Show forest plot

2

44

Mean Difference (IV, Random, 95% CI)

‐0.44 [‐2.27, 1.38]

9 Health‐related quality of life Show forest plot

4

95

Std. Mean Difference (IV, Random, 95% CI)

‐0.56 [‐1.27, 0.15]

10 Minor adverse events related to intervention Show forest plot

6

144

Risk Difference (M‐H, Random, 95% CI)

0.0 [‐0.05, 0.05]

Figures and Tables -
Comparison 2. Neuromuscular electrostimulation (NMES) plus exercise versus exercise only